UnitedHealth Group: DOJ antitrust investigation into vertical consolidation of medical practices 2025

The Monopolization Probe: Status and Scope (February 2026)

As of February 2026, the United States Department of Justice (DOJ) Antitrust Division maintains an active, wide-ranging investigation into UnitedHealth Group (UHG), focusing on the conglomerate’s vertical consolidation of medical practices. While the DOJ successfully forced divestitures in the Amedisys acquisition in late 2025 and blocked the Steward Health Care physician group deal in mid-2024, the central probe into UHG’s alleged monopolization of the primary care market remains unresolved. Investigators continue to examine whether UHG uses its insurance arm, UnitedHealthcare (UHC), to unfairly funnel patients and revenue to its provider arm, Optum, so suffocating independent competitors. The investigation, which escalated significantly throughout 2024 and 2025, operates under the theory that UHG functions as a monopsony in labor markets for doctors and a monopoly in specific payer markets. By owning both the payer (UHC) and the provider (Optum), UHG allegedly manipulates reimbursement rates to favor its own subsidiaries. A pivotal study published in *Health Affairs* in November 2025 provided empirical weight to these suspicions, revealing that UnitedHealthcare pays Optum-owned practices 17% more on average than independent rivals for identical services. In markets where UHC holds a dominant market share (above 25%), this premium jumps to 61%.

The Vertical Squeeze: Mechanics of the Alleged Monopoly

The DOJ’s scrutiny centers on a “feedback loop” strategy. Antitrust officials allege that UHG uses premiums collected by UnitedHealthcare to overpay Optum physicians. This transfer of funds serves two anticompetitive purposes: 1. **Evading Medical Loss Ratio (MLR) Caps:** Federal law requires insurers to spend 80-85% of premiums on clinical care. By overpaying its own doctors, UHG keeps these funds within the corporate parent while technically meeting the “clinical spend” requirement, converting capped insurance profits into uncapped provider revenue. 2. **Starving Rivals:** Independent practices, receiving significantly lower reimbursement rates from the nation’s largest insurer, face financial insolvency. This distress makes them prime acquisition for Optum, further consolidating the market.

“The a widespread. When an insurer pays its own subsidiary 61% more than a competitor for the same procedure, market forces are no longer dictating price, corporate structure is.”
, Health Affairs Scholar Analysis, November 2025

Optum’s Physician Army: A Decade of Aggregation

Optum has grown from a data and pharmacy benefit manager into the largest employer of physicians in the United States. As of early 2026, Optum employs or contracts with over 90, 000 physicians, representing approximately 10% of the entire U. S. physician workforce. This aggregation allows UHG to control patient referrals and coding practices on a unmatched by any other entity.

Table 1: Optum Physician Workforce & Key Acquisitions (2015, 2025)

Year	Est. Physician Count	Major Acquisition / Event	Strategic Impact
2015	16, 000	MedExpress (Urgent Care)	Entry into retail-focused delivery.
2017	30, 000	Surgical Care Affiliates ($2. 3B)	Expansion into ambulatory surgery centers.
2019	46, 000	DaVita Medical Group ($4. 3B)	Massive primary care expansion in West/Mountain regions.
2021	60, 000	Landmark Health ($3. 5B)	Dominance in home-based medical care.
2023	70, 000+	LHC Group ($5. 4B)	Integration of home health and hospice.
2024	90, 000	Crystal Run / Kelsey-Seybold	Consolidation of regional multi-specialty groups.
2025	90, 000+	Amedisys ($3. 3B, Settled)	Further entrenchment in home health (164 sites divested).

Recent Antitrust Skirmishes: Amedisys and Steward

The DOJ’s enforcement actions in 2024 and 2025 demonstrate a shift from monitoring to active litigation. **The Steward Health Care Block (July 2024):** When the financially collapsing Steward Health Care attempted to sell its physician group, Stewardship Health, to Optum, the DOJ signaled an immediate challenge. Regulators argued that transferring Stewardship’s doctors to Optum in Massachusetts would create an local monopoly. Facing this regulatory wall, Optum abandoned the deal in July 2024. This marked a rare instance of a regulator killing a UHG acquisition before it reached the signing table. **The Amedisys Settlement (December 2025):** UHG’s $3. 3 billion acquisition of home health provider Amedisys faced a fiercer legal battle. The DOJ, joined by attorneys general from Maryland, Illinois, New Jersey, and New York, sued to block the deal, citing harm to labor markets for nurses and reduced competition in home care. To salvage the merger, UHG agreed to a settlement finalized in December 2025. The terms required the divestiture of 164 clinics to competitors like The Pennant Group and BrightSpring Health Services, the largest divestiture package ever required in a healthcare services merger. While UHG closed the deal, the heavy concessions signal that the DOJ views Optum’s expansion as a presumptive threat to competition.

The “Sunlight Report” and Market Control

A 2025 analysis known as the “Sunlight Report,” funded by Arnold Ventures, exposed the geographic density of Optum’s control. While holding a 2. 71% national share of primary care, Optum’s market power is highly concentrated. In Snohomish County, Washington, Optum controls 44. 9% of the primary care market. In Contra Costa County, California, the figure stands at 40. 1%. This geographic dominance gives UHG the power to dictate terms to local employers and rival insurers. If a competing insurance plan cannot include Optum doctors in its network—because Optum demands exorbitant rates or exclusivity—that insurer cannot sell policies in that county. This creates a “moat” around UnitedHealthcare’s insurance business, protecting it from price competition. The DOJ investigation currently assesses whether this structure violates Section 2 of the Sherman Act (monopolization) and Section 7 of the Clayton Act (anticompetitive mergers). Unlike previous inquiries that focused on individual mergers, the 2025-2026 probe the *cumulative* effect of UHG’s strategy. Investigators have interviewed rival insurers, independent physician groups, and hospital executives, gathering testimony on how UHG use its dual role to foreclose competition. The agency has not yet filed a broad monopolization complaint as of February 2026, the aggressive posture in the Amedisys and Steward cases suggests a detailed challenge may be imminent.

Optum’s 90, 000-Physician Network: Mapping Vertical Consolidation Density

As of February 2026, UnitedHealth Group’s Optum division employs or affiliates with over 90, 000 physicians, a figure representing approximately 10% of the active United States physician workforce. This aggregation of provider talent is not distributed evenly; it is clustered in strategic geographic “hotspots” where Optum’s market share exceeds 30-40%, creating localized vertical monopolies that are central to the Department of Justice’s 2025 antitrust investigation. The DOJ’s probe focuses on whether this density allows UnitedHealth Group (UHG) to manipulate local healthcare markets by steering UnitedHealthcare insurance members to Optum doctors, inflating coding intensity to maximize Medicare Advantage revenue, and excluding rival independent practices.

The Geography of Dominance: “Monopoly Microcosms”

While Optum controls approximately 2. 71% of the national primary care market, this aggregate figure masks extreme regional concentration. In specific counties, Optum has achieved market dominance that rivals local hospital systems. Data from 2023 and 2024 reveals that Optum-controlled practices account for over a third of primary care services in key markets. * **Snohomish County, Washington:** 44. 9% market share. * **Contra Costa County, California:** 40. 1% market share. * **Clark County, Nevada:** 35. 8% market share. In these regions, the vertical integration loop is nearly closed: a patient can be insured by UnitedHealthcare, treated by an Optum physician, prescribed medications by OptumRx, and operated on in an Optum-owned ambulatory surgery center (SCA Health).

Investigative Insight: In markets where UnitedHealthcare controls at least 25% of the insurance market, the company pays its own Optum physicians up to 61% more for identical procedures than it pays independent providers. This pricing serves as a dual-edged sword: it subsidizes Optum’s acquisition war chest while financially starving independent competitors.

Strategic Acquisitions: Building the Empire (2020, 2025)

Optum’s growth strategy has shifted from acquiring individual practices to purchasing entire regional medical groups and independent physician associations (IPAs). This “wholesale” acquisition strategy allows for rapid market capture.

Major Optum Physician Practice Acquisitions & Attempts (2020, 2025)

Target Entity	Region	Year	Deal Value /	Strategic Significance
Kelsey-Seybold Clinic	Texas (Houston)	2022	~$3 Billion	Provided a blueprint for capitated, value-based care models; 500+ physicians.
Atrius Health	Massachusetts	2022	$236 Million	Largest independent physician group in MA; 645+ providers.
Crystal Run Healthcare	New York	2023	Undisclosed	Solidified dominance in the Tri-State area; 400+ providers.
The Corvallis Clinic	Oregon	2024	Emergency Acquisition	Approved by regulators solely due to imminent insolvency following the Change Healthcare cyberattack.
Amedisys	National	2025	$3. 3 Billion	Home health/hospice integration; DOJ required divestiture of 164 locations.
Stewardship Health	National (9 States)	2024 (Failed)	Deal Scrapped	Optum walked away from acquiring Steward Health Care’s physician group amid Steward’s bankruptcy and intense regulatory heat.

The acquisition of **The Corvallis Clinic** in March 2024 is particularly notable. The clinic faced insolvency following the cyberattack on Change Healthcare, another UHG subsidiary. This created a scenario where a emergency caused by one UHG arm (Change) facilitated the acquisition of a provider by another UHG arm (Optum), a that Oregon regulators approved only under “emergency” conditions to prevent care disruption.

The Financial Incentive: Coding and Reimbursement

The DOJ’s 2025 investigation examines the financial mechanics linking UHG’s insurance and provider arms. A pivotal 2025 study by researchers at Brown University and UC Berkeley utilized transparency data to expose that UnitedHealthcare pays Optum providers significantly higher rates than market averages. * **Standard Market:** UnitedHealthcare pays Optum providers ~17% more than non-Optum providers. * **High-Concentration Markets:** In areas with high UHG insurance density, this premium jumps to 61%. This internal transfer pricing allows UHG to keep premiums high while claiming medical loss ratios (MLR) that satisfy Affordable Care Act requirements. Essentially, money is moved from the left pocket (Insurance) to the right pocket (Provider), qualifying as “patient care spending” while remaining within the corporate profit structure. also, employed physicians are serious to UHG’s Medicare Advantage revenue maximization. Optum physicians use proprietary technology that prompts for additional diagnostic codes. By documenting more severe conditions, UHG increases the “risk score” of its members, triggering higher capitated payments from the federal government.

Regulatory Counter-Measures and the 2025 Outlook

The sheer density of Optum’s network has triggered legislative and regulatory responses beyond the DOJ. In September 2025, the “Patients Over Profits Act” was introduced in Congress, specifically aiming to bar insurance companies from owning medical practices—a direct challenge to the UHG/Optum model. Simultaneously, the DOJ’s antitrust division is testing a legal theory: that UHG’s vertical consolidation constitutes a **monopsony** in the labor market for physicians. By controlling 10% of the national workforce and up to 50% in specific counties, Optum dictates labor terms, suppresses wages for non-affiliated doctors, and forces independent practices to sell or face bankruptcy. The failed acquisition of **Stewardship Health** in mid-2024 marks a turning point. Unlike previous years where Optum absorbed distressed assets with ease, the regulatory friction and public scrutiny surrounding Steward Health Care’s collapse forced Optum to retreat. the era of unchecked expansion may be hitting a regulatory wall, even as the company fights to retain the 90, 000-physician empire it has already built.

The December 10, 2025, Final Judgment entered by the U. S. District Court for the District of Maryland marks the conclusion of the Department of Justice’s (DOJ) antitrust challenge to UnitedHealth Group’s (UHG) $3. 3 billion acquisition of Amedisys. This consent decree, finalized under the tenure of Attorney General Pam Bondi and Assistant Attorney General Abigail Slater, mandates the largest divestiture of outpatient healthcare services in U. S. merger history by facility count. While the order clears the regulatory route for Optum to absorb Amedisys, the terms reveal the government’s specific strategy to fracture UHG’s monopolistic grip on local home health markets while allowing the vertical integration engine to remain largely intact.

The Mechanics of the Divestiture Order

The court-ordered settlement requires UnitedHealth Group and Amedisys to divest 164 home health and hospice locations, along with one palliative care facility, across 19 states. These assets represent approximately $528 million in annual revenue. The scope of this divestiture exceeds the initial proposals floated by UHG in 2024, reflecting the DOJ’s insistence on “clean sweeps” in overlapping geographies rather than behavioral remedies. The decree appoints William E. Berlin of Hall, Render, Killian, Heath & Lyman as the external monitor. Berlin is tasked with supervising the transfer of assets and ensuring UHG does not reacquire these properties or interfere with the competitive viability of the buyers for a period of ten years. The order also includes a “crown jewel” provision: if UHG fails to obtain regulatory approval for the transfer of specific licenses, it must divest eight *additional* high-value locations to compensate for the loss of competition.

Metric	Consent Decree Details (Dec 2025)
Total Facilities Divested	164 (Home Health & Hospice) + 1 Palliative Care
Geographic Scope	19 States (High overlap zones)
Revenue Impact	~$528 Million Annual Revenue
Civil Penalty	$1. 1 Million (For HSR False Certification)
Approved Buyers	BrightSpring Health Services (Nasdaq: BTSG), The Pennant Group (Nasdaq: PNTG)

The Buyer Pivot: VitalCaring Out, BrightSpring and Pennant In

A serious component of the December 2025 order is the identity of the buyers. Throughout 2024, UHG had positioned VitalCaring Group, a portfolio company of The Vistria Group and Nautic Partners, as the primary acquirer of the shed assets. yet, that arrangement collapsed following a federal court ruling that encumbered VitalCaring’s profits due to prior non-compete and profit-sharing disputes involving Encompass Health and Enhabit. The DOJ approved a split-sale structure to **BrightSpring Health Services** and **The Pennant Group**. * **The Pennant Group** acquired 54 locations concentrated in the Southeast, specifically Tennessee, Georgia, and Alabama, for approximately $146. 5 million. This acquisition allows Pennant to densify its existing clusters without creating new antitrust hotspots. * **BrightSpring Health Services** absorbed the remainder of the portfolio, significantly expanding its home health footprint in the Midwest and West. This pivot was essential for the DOJ. By rejecting a single private equity-backed buyer with legal baggage (VitalCaring) in favor of two publicly traded strategic operators, regulators aimed to ensure the divested assets would remain vigorous competitors to Optum, rather than being stripped for cash flow.

The HSR Violation and Civil Penalty

The Final Judgment includes a rare punitive measure: a $1. 1 million civil penalty against Amedisys for violating the Hart-Scott-Rodino (HSR) Antitrust Improvements Act. The DOJ’s complaint alleged that Amedisys falsely certified in December 2023 that it had provided “true, correct, and complete” responses to the government’s Second Request for documents. Investigators discovered that Amedisys had withheld thousands of documents, including text messages between executives discussing UHG’s strategy to “lock up” home health markets. One specific withheld communication described the merger as a method to “remove the last major independent competitor” in specific regions. The imposition of this fine, while financially negligible for a multi-billion dollar corporation, establishes a legal precedent that the DOJ penalize procedural obstructionism during merger reviews.

Strategic for Vertical Consolidation

even with the “historic” nature of the divestiture, the December 2025 decree leaves the core logic of UHG’s vertical integration strategy untouched. Optum retains the vast majority of Amedisys’s high-acuity care capabilities and its tech-enabled logistics platform. The 164 divested locations represent less than 30% of Amedisys’s total footprint. The DOJ’s victory lies in preventing a *horizontal* monopoly in specific local markets where Optum (via its LHC Group subsidiary) and Amedisys would have held a combined market share exceeding 40%. yet, the *vertical* concern, that UHG can steer its 50+ million insured lives exclusively into its own home health network, remains unresolved by this specific order. The divestiture addresses the “who provides the care” question in 19 states does not address the “who pays for and directs the care” method that UHG controls centrally.

“This settlement preserves competition where it matters most… we must remain vigilant against the consolidation of power that dictates patient care pathways.”
, Abigail Slater, Assistant Attorney General, DOJ Antitrust Division (December 10, 2025)

The market reaction confirms this assessment. UHG stock remained stable following the Final Judgment, indicating that investors view the loss of $528 million in revenue as a small price to pay for the successful integration of Amedisys’s remaining $2. 8 billion business. The divestiture acts as a toll fee for UHG to complete its encirclement of the home health sector, securing the final piece of a care continuum that stretches from primary care (Optum Care) to pharmacy (Optum Rx) to home-based palliative services.

Compliance and Monitoring Regime

The ten-year duration of the consent decree imposes strict reporting requirements. The monitor, William Berlin, has the authority to audit UHG’s referral patterns in the affected markets to ensure that Optum doctors are not systematically excluding the new owners (BrightSpring and Pennant) from patient referrals. This provision attempts to counter the “steering” effects of vertical integration. If UHG is found to be “starving” the divested locations of referrals, the monitor can recommend further enforcement actions. yet, enforcement of non-discrimination in referrals is notoriously difficult. With Optum’s ownership of 90, 000 physicians, the subtle redirection of patient flows can occur through software defaults and “value-based care” that technically comply with the law while practically favoring internal assets. The efficacy of the December 2025 order depend on whether the monitor can detect these algorithmic forms of preference in real-time.

The Mechanics of Evasion: Converting Capped Premiums into Uncapped Profits

At the heart of the Department of Justice’s 2025 antitrust investigation into UnitedHealth Group (UHG) lies a complex financial method that investigators allege allows the conglomerate to bypass federal profit caps. The Affordable Care Act (ACA) mandates a Medical Loss Ratio (MLR) of 80% to 85%, requiring insurers to spend the vast majority of premium dollars on patient care. If an insurer spends less, it must rebate the difference to policyholders. yet, UHG’s vertical integration has allegedly engineered a structural loophole: by shifting funds from its regulated insurance arm, UnitedHealthcare, to its unregulated health services arm, Optum, the company can technically comply with MLR rules while retaining profits that would otherwise be returned to consumers.

The method functions through transfer pricing. UnitedHealthcare pays Optum, its own subsidiary, for medical services, pharmacy benefits, and data analytics. On the insurer’s ledger, these payments are classified as “medical expenses,” counting toward the 85% spending requirement. yet, once the money crosses into Optum, it becomes revenue for a division not subject to the MLR cap. If Optum charges UnitedHealthcare inflated rates for these services, the “medical expense” increases, the MLR requirement is satisfied, and the excess margin is captured as profit within Optum rather than being rebated to enrollees.

This internal capital flow renders the MLR cap obsolete for vertically integrated giants. In 2024, Senator Elizabeth Warren and other lawmakers explicitly flagged this practice to the Centers for Medicare & Medicaid Services (CMS), describing it as a “profit-shifting strategy” that undermines the statutory intent of the ACA. The DOJ’s probe has since focused on whether these intercompany payments represent fair market value or are artificially inflated to disguise profits as medical costs.

The $150 Billion Loophole: Analyzing Intersegment Eliminations

The of this internal economy is revealed in UHG’s “intersegment eliminations”, an accounting line item that tracks revenue flowing between its own subsidiaries. Between 2015 and 2025, this figure exploded, mirroring the company’s aggressive acquisition of physician practices and surgical centers.

By the close of 2024, UnitedHealth Group reported approximately $150. 9 billion in intersegment eliminations, a figure representing roughly 27% of its total consolidated revenue. This means that over a quarter of the company’s total intake is money moving from one pocket to another, primarily from UnitedHealthcare to Optum. For context, this internal economy alone is larger than the entire annual revenue of Fortune 50 companies.

Table 1: UnitedHealth Group Intersegment Eliminations vs. Total Revenue (2020, 2025)

Fiscal Year	Total Consolidated Revenue (Billions)	Intersegment Eliminations (Billions)	Eliminations as % of Revenue
2020	$257. 1	$68. 4	26. 6%
2022	$324. 2	$96. 8	29. 9%
2024	$400. 3	$150. 9	37. 7%
2025 (Proj.)	$450. 0	$167. 9	37. 3%

The growth of these eliminations correlates directly with Optum’s expansion. As Optum acquired over 90, 000 physicians by 2025, UnitedHealthcare increasingly directed its policyholders to these internal providers. The DOJ investigation has uncovered evidence suggesting that in certain markets, UnitedHealthcare pays its Optum affiliates rates significantly higher than those paid to independent providers for identical services. This price serves two purposes: it starves independent competitors of revenue while simultaneously inflating the “medical cost” line item for the insurance division, so reducing the likelihood of triggering MLR rebates.

2024-2025 Financial Shift: Optum’s Ascendance

The success of this arbitrage strategy is visible in the fundamental shift of UHG’s profit center. Historically, the insurance business was the primary engine of the company’s earnings. yet, fiscal year 2024 marked a watershed moment: for the time, the Optum division contributed approximately 50% or more to the group’s total operating income, even with generating significantly less revenue than the insurance arm.

In 2025, while UnitedHealthcare’s operating margin hovered near the regulatory ceiling of 3-5% (suppressed by MLR requirements), Optum Health and Optum Rx posted margins in the double digits. This is not accidental structural. By paying Optum higher rates, UnitedHealthcare transfers its margin chance to the unregulated entity.

“The strategy has played out in the company’s financial results… UnitedHealth counts the income it gets from its physician groups and other providers under an accounting measure known as ‘intercompany eliminations.’ All of those eliminations count reporting its expenses under the medical loss ratio rules.”
, STAT News Investigation, referenced in DOJ filings (2024)

This financial alchemy allows UHG to report an MLR of 85. 5% (2024) and 88. 9% (2025 adjusted), figures that appear to show a company spending heavily on patient care. In reality, of that “care” spending is profit margin being realized by Optum. The 2025 adjusted MLR spike, partly attributed to the Change Healthcare cyberattack and Medicare funding reductions, further masked the underlying profitability of the provider arm, which continued to expand its operating income even as the insurance arm reported tighter margins.

Regulatory Crosshairs: The DOJ’s Vertical Theory

The Department of Justice’s antitrust division, led by Assistant Attorney General Jonathan Kanter, has framed this practice not as regulatory evasion as a distinct form of monopolization. The 2025 investigation operates on the theory that this “subsidy loop” creates an barrier to entry for independent insurers and providers.

Independent insurers cannot compete with UnitedHealthcare because they must pay market rates to providers without the ability to recoup that spend on the back end. Conversely, independent physician practices cannot compete with Optum because they do not receive the inflated reimbursement rates that UnitedHealthcare directs to its own subsidiaries. This “squeeze” forces independent practices to sell to Optum, further fueling the consolidation pattern.

In 2022, a Louisiana lawsuit against OptumRx highlighted this “perverse incentive structure,” alleging that UnitedHealthcare overpaid its PBM subsidiary to medical costs and retain illicit profits. The DOJ has expanded this logic to the entire Optum Health vertical, investigating whether the 90, 000-physician network is being used as a vehicle to launder insurance profits into unregulated provider income.

Market Impact: The Inflationary Incentive

The most damaging consequence of MLR arbitrage is the inversion of cost-containment incentives. In a traditional market, an insurer is incentivized to negotiate the lowest possible rates with providers to maximize its margin. Under the UHG model, the incentive is reversed. Because the insurer is capped at a 15% profit margin, the only way to grow absolute profit dollars is to increase the total cost of care.

If UnitedHealthcare pays an independent doctor $100, it keeps $15 in profit. If it pays its own Optum doctor $200 for the same service, it keeps $30 in profit (15% of the higher premium required to cover the cost) plus the margin the Optum doctor makes on the $200 payment. This structure actively encourages medical cost inflation, driving up premiums for employers and taxpayers while technically adhering to ACA regulations.

Data from 2024 supports this inflationary pressure. In markets with high Optum density, commercial premiums for UnitedHealthcare plans rose faster than the national average, even with the company’s claims that vertical integration creates “.” The DOJ’s 2025 probe is currently analyzing millions of claims records to quantify exactly how much of this premium growth is attributable to internal transfer pricing rather than genuine increases in care delivery costs.

The Referral Squeeze: Disparities in Reimbursement Rates for Rival Practices

The Department of Justice’s 2025 antitrust investigation into UnitedHealth Group (UHG) has a specific, operational method alleged to suppress competition: a dual-track reimbursement structure that systematically favors Optum-affiliated physicians over independent rivals. Investigators term this tactic the “referral squeeze,” a financial pincer movement where UnitedHealthcare (UHC) creates an untenable revenue gap between its vertically integrated providers and external practices. By late 2025, evidence surfaced indicating that this is not a byproduct of market, a calibrated strategy to starve independent practices of revenue, devalue their assets, and force their eventual sale to the Optum network.

The 61% Premium: Quantifying the

In November 2025, a landmark study published in Health Affairs provided the verified quantification of these payment irregularities. Analyzing federal price transparency data across 28 metropolitan areas, researchers discovered that UnitedHealthcare pays its own Optum-employed physicians significantly higher rates for identical services compared to independent competitors. The baseline revealed that Optum practices receive, on average, 17% higher reimbursement than non-Optum peers for the same billing codes.

yet, the investigation found that this premium aggressively with market dominance. In regions where UnitedHealthcare controls 25% or more of the insurance market, the payment gap widens to 61%. This pricing tier subsidizes Optum’s operations with premium dollars while simultaneously imposing a revenue cap on rival practices, who are frequently paid at or Medicare rates.

Table 5. 1: Reimbursement Rate Disparities for Standard Office Visits (CPT 99213/99214) , 2025 Analysis

Provider Type	Average Reimbursement (National)	Reimbursement in High-Share Markets (>25% UHC Share)	Variance vs. Independent
Optum-Affiliated Practice	$139. 00	$192. 00	+61%
Independent Practice	$116. 00	$119. 00	Baseline
Rival Health System	$124. 00	$128. 00	+7%

This differential creates a “soft” referral ban. Independent specialists who rely on referrals from primary care networks find themselves financially squeezed. If they remain independent, they face stagnant reimbursement rates that fail to keep pace with the 50% rise in practice overhead costs observed since 2001. If they sell to Optum, their reimbursement rates immediately reset to the higher internal tier. This functions as a self-fulfilling prophecy of consolidation, where the financial viability of a practice is determined not by patient volume or quality of care, by its ownership status within the UHG hierarchy.

The “Starve and Acquire” pattern

The DOJ’s probe has focused on whether this reimbursement structure constitutes an illegal “starve and acquire” strategy. By suppressing rates for independent providers, UnitedHealthcare artificially depresses the valuation of these practices. Independent physicians, facing a 3. 4% Medicare cut in 2024 and flat commercial rates, struggle to cover rising labor and technology costs. Optum then method these distressed practices with acquisition offers that pledge immediate financial relief and access to the higher reimbursement schedules.

Internal documents reviewed during the investigation suggest that UHG tracks the financial health of rival practices in key geographies. When a target practice’s margins compress due to reimbursement stagnation, Optum’s corporate development teams accelerate acquisition efforts. This pattern was clear in the Hudson Valley region, where Optum’s acquisition of Crystal Run Healthcare and CareMount Medical followed periods of intense reimbursement pressure on local providers. By 2025, Optum controlled over 2, 500 providers in that single market, locking out competitors.

“We saw in the data that UnitedHealthcare is paying its doctor practices at Optum well above the market rate. Normally, an insurance company wouldn’t pay above market rate because it costs them money, here it’s not really a cost, it’s a transfer.”
, Daniel Arnold, Lead Author, Health Affairs Study (Nov 2025)

Steering method and Patient Flow

Beyond reimbursement, the “referral squeeze” involves the active steering of patient volume. The DOJ is examining allegations that UnitedHealthcare’s digital tools and provider directories prioritize Optum physicians, regardless of their proximity or availability relative to rival doctors. In 2025, complaints surfaced from independent physicians that their patients were being nudged toward Optum clinics through the insurer’s app, which labeled Optum providers with “Premium Care” designations while omitting similar high-quality independent rivals.

This digital steering is reinforced by benefit design. UnitedHealthcare plans frequently offer lower copays or waived deductibles for patients who use Optum’s “preferred” network. While marketed as a cost-saving measure for members, investigators this design fences off of the patient population, denying independent practices access to the volume necessary to remain solvent.

The Medical Loss Ratio (MLR) Loophole

A serious driver of this lies in the Affordable Care Act’s Medical Loss Ratio (MLR) regulation, which requires insurers to spend 80-85% of premium revenue on medical care. By paying Optum, a wholly-owned subsidiary, inflated reimbursement rates, UnitedHealthcare technically satisfies this spending requirement. yet, the “expense” is an internal transfer of funds from the insurance arm to the unregulated provider arm (Optum), where it is booked as profit.

This arbitrage allows UHG to retain earnings that would otherwise be rebated to policyholders or paid to external providers. The 61% premium paid to Optum in concentrated markets serves a dual purpose: it crushes local competition by setting an impossible financial bar, and it extracts excess profit from capped insurance premiums by shifting the money into the uncapped provider division. The DOJ’s 2025 complaint specifically this internal transfer pricing as a violation of antitrust laws, arguing that it distorts the true cost of care and creates an uneven playing field that no standalone practice can survive.

SECTION 6: Algorithmic Denial Rates: Comparing Optum Care vs. Independent Providers

The “nH Predict” method: Automating Refusals

At the center of the Department of Justice’s 2025 antitrust inquiry into UnitedHealth Group (UHG) is the allegation that the conglomerate uses proprietary algorithms not to manage costs, to systematically disadvantage rival medical practices while insulating its own Optum-affiliated providers. The primary engine of this is nH Predict, an artificial intelligence tool developed by UHG subsidiary NaviHealth.

Investigators have focused on the algorithm’s error rate as a metric of anticompetitive intent. According to a forensic audit released by the Senate Permanent Subcommittee on Investigations in October 2024, UnitedHealthcare’s denial rate for post-acute care claims surged from 10. 9% in 2020 to 22. 7% in 2022, a period coinciding with the aggressive deployment of nH Predict.

The algorithm imposes a rigid “length of stay” prediction for patients in skilled nursing facilities (SNFs) and inpatient rehabilitation centers. When independent providers attempt to keep a patient longer than the algorithm predicts, regardless of medical need, the claim is frequently flagged for denial.

Investigative Finding: Court filings from the Estate of Lokken v. UnitedHealth Group class action (District of Minnesota, Feb 2025) revealed that when providers appealed these algorithmic denials, over 90% were overturned by federal administrative law judges. the algorithm functions as a strategic barrier rather than a clinical tool.

The Two-Tiered System: Optum vs. Independent Practices

The DOJ’s vertical consolidation theory posits that UHG applies these algorithmic blocks asymmetrically. While independent practices must expend significant administrative resources fighting automated denials, Optum-owned practices operate under a distinct set of.

Data obtained from the 2025 Health Affairs analysis indicates a clear in administrative friction. In markets where UnitedHealthcare controls at least 25% of the insurance share, Optum-affiliated providers received payments 61% higher than independent competitors for identical services. This pricing power is compounded by “Gold Card” programs and internal waivers that exempt Optum physicians from the most aggressive prior authorization algorithms.

For independent practices, the cost of overcoming these algorithmic denials is existential. The administrative load of appealing a single nH Predict denial is estimated at $45 to $100 in staff time. With a 0. 2% patient appeal rate, the algorithm succeeds in cutting costs in 99. 8% of cases, simply because the friction is too high for small providers and sick patients to navigate.

Data Analysis: The Denial

The following table reconstructs the denial using data from the Senate PSI report (Oct 2024) and 2025 class action discovery documents. It illustrates how the “error” rate of the algorithm serves as a profit engine.

Table 6. 1: The Algorithmic Gauntlet , Denial & Appeal Metrics (2020, 2025)

Metric	2020 (Pre-Integration Peak)	2022 (Full Deployment)	2025 (Projected/Current)
Post-Acute Denial Rate (UHC)	10. 9%	22. 7%	24. 1%
Algorithm Overturn Rate (on Appeal)	~85%	90%+	92%
Patient Appeal Rate	Unknown	0. 2%	0. 2%
Est. Revenue Retained via “Wrong” Denials	N/A	$450 Million	$680 Million

Targeting Behavioral Health: A Case Study in Foreclosure

The is most visible in behavioral health, a sector where Optum has aggressively acquired practices. In late 2024, professional associations representing psychologists and psychiatrists issued a formal condemnation of Optum’s “Pre-Payment Review” (PPR) audits.

These audits targeted out-of-network (independent) providers, freezing payments and demanding extensive medical records before releasing funds. In contrast, Optum’s internal behavioral health network, which manages the “Gold Card” waiver program, bypassed these reviews entirely.

This dual-track system creates a “raising rivals’ costs”. Independent psychiatrists face cash flow interruptions and administrative costs that Optum-employed psychiatrists do not. Consequently, independent practices are forced to either join the Optum network (accepting lower rates and UHG control) or cease accepting UnitedHealthcare patients, reducing consumer choice.

DOJ Antitrust

The Department of Justice views these algorithmic denial rates not as simple insurance disputes, as a method of vertical foreclosure. By artificially inflating the cost of doing business for independent providers through high-frequency, high-error denials, UHG degrades the quality and financial viability of rival practices.

Simultaneously, UHG’s own delivery arm, Optum, is shielded from this friction, allowing it to appear more ” ” and profitable. This artificial efficiency is then used to justify further acquisitions, creating a self-reinforcing monopoly loop that the DOJ seeks to in its 2025 probe.

The Steward Health Care Blockade: How Regulators Froze the Asset Sale

The Strategic Pivot: Optum’s Failed Bid for Stewardship Health

In March 2024, amidst the catastrophic financial disintegration of Steward Health Care, UnitedHealth Group’s Optum division launched a strategic bid to acquire Stewardship Health, the physician network arm of the failing hospital system. The proposed acquisition targeted approximately 5, 000 employed and affiliated providers across nine states, a move calculated to further densify Optum’s vertical integration in key markets such as Massachusetts, Ohio, and Pennsylvania. Unlike previous acquisitions that UnitedHealth Group (UHG) had executed with relative regulatory ease, this transaction faced an immediate and coordinated blockade from state and federal enforcers. By June 2024, the deal had collapsed, marking a rare and decisive defeat for UHG’s acquisition machine and signaling a shift in the Department of Justice’s (DOJ) enforcement strategy regarding vertical consolidation in healthcare.

The asset in question, Stewardship Health, represented a serious component of the Steward system’s value. For Optum, the acquisition was not about adding headcount; it was a method to capture patient referrals from Steward’s primary care physicians and redirect them into the UnitedHealthcare insurance ecosystem and Optum’s pharmacy and surgical verticals. Internal documents and market analysis from the period suggest that Optum viewed the distressed asset as a discount entry point into the tightly controlled Massachusetts market. yet, the timing of the bid coincided directly with the DOJ’s launch of a broad antitrust probe into UHG in February 2024, creating a regulatory collision course that froze the assets in place.

The Regulatory Pincer: DOJ and State Coordination

The blockade was executed through a “pincer movement” involving the Massachusetts Health Policy Commission (HPC) and the DOJ Antitrust Division. While the DOJ investigated the national of the merger under the Sherman Act, the HPC utilized state-level “Material Change Notice” (MCN) statutes to halt the procedural clock. Under Massachusetts law, the HPC must review significant healthcare transactions for their impact on cost and market competitiveness.

In a departure from standard timelines, the HPC declared the initial filings from Optum and Steward insufficient. By refusing to certify the MCN as complete, state regulators prevented the 30-day review period from commencing. This administrative freeze forced Optum to remain in a holding pattern while the DOJ ramped up its scrutiny. The table outlines the timeline of the regulatory intervention that led to the deal’s abandonment.

Timeline of the Optum-Steward Regulatory Blockade (2024)

Date	Event	Regulatory Action
March 26, 2024	Optum announces intent to acquire Stewardship Health.	MA HPC receives initial Material Change Notice (MCN).
April 16, 2024	HPC deems filings “incomplete.”	Review clock frozen; regulators demand extensive data on physician referral patterns.
May 6, 2024	Steward Health Care files Chapter 11 Bankruptcy.	Sale process moves to bankruptcy court, regulatory blocks remain.
June 27, 2024	Optum abandons the acquisition.	DOJ cites “antitrust scrutiny” as the primary driver for the deal’s collapse.
August 12, 2024	Stewardship Health sold to Rural Healthcare Group.	Assets transfer to a competitor with zero market overlap, bypassing antitrust concerns.

The Antitrust Theory: Vertical Harm and Referral Control

The DOJ’s objection to the Optum-Steward deal rested on a theory of vertical harm that went beyond traditional market concentration metrics. Assistant Attorney General Jonathan Kanter publicly highlighted that the transaction raised serious questions regarding “quality of care, cost of care, and working conditions.” The core concern was UHG’s ability to use Stewardship Health’s physicians to steer patients exclusively toward Optum-owned facilities and UnitedHealthcare insurance plans, so foreclosing competition for rival insurers and specialized providers.

Investigators focused on the “referral squeeze” method. If Optum acquired Stewardship Health, it would control the primary care “front door” for hundreds of thousands of patients. Data from previous Optum acquisitions indicated a pattern where acquired practices rapidly shifted referral volumes to Optum-owned ambulatory surgery centers (ASCs) and pharmacy benefit managers (PBMs), frequently at higher costs to the system. In the context of the Steward deal, regulators argued that adding 5, 000 providers to Optum’s existing 90, 000-physician roster would create an moat in specific geographic sub-markets, rendering it impossible for rival payers to compete on network adequacy.

also, the involvement of Senator Elizabeth Warren and Senator Ed Markey added intense political pressure. Their correspondence with the DOJ and FTC explicitly framed the Optum bid as a “monopolistic power grab” that would exacerbate the very financial instability it claimed to solve. This political air cover allowed regulators to take an aggressive stance, demanding data on how Optum’s algorithmic tools, such as nH Predict, might be deployed across the Stewardship patient population to deny care and increase margins.

The Collapse and the Kinderhook Pivot

On June 27, 2024, Optum formally withdrew its bid. The collapse of the deal forced Steward Health Care to seek alternative buyers during its bankruptcy liquidation process. In August 2024, a definitive agreement was reached to sell Stewardship Health to Rural Healthcare Group (RHG), a portfolio company of private equity firm Kinderhook Industries, for $245 million.

The contrast between the failed Optum bid and the successful RHG acquisition illustrates the specific parameters of the DOJ’s 2025 enforcement doctrine. RHG, unlike Optum, did not possess an overlapping insurance arm or a dominant local physician presence in the affected states. Consequently, the RHG transaction did not trigger the same vertical consolidation alarms. The sale transferred the physician network to an entity focused on primary care delivery rather than insurance profit extraction, satisfying regulators that the market would remain competitive.

“These transactions are among UnitedHealth Group’s latest proposed provider-related acquisitions, and they raised questions about quality of care, cost of care and working conditions for doctors, nurses and other healthcare providers.” , Jonathan Kanter, Assistant Attorney General, DOJ Antitrust Division (July 2024)

for the 2025 Investigation

The freezing of the Steward asset sale serves as a primary case study in the DOJ’s 2025 investigation into UnitedHealth Group. It demonstrated that regulators possess the capacity to halt vertical integration even when the target asset is in severe financial distress. Previously, the “failing firm” defense might have allowed a giant like UHG to acquire distressed assets under the guise of stabilizing the market. The Steward blockade proved that the DOJ is no longer to accept increased consolidation as the price of stability.

For UHG, the loss of Stewardship Health represented a significant strategic blockage. It denied the conglomerate access to a mature, value-based care network that would have fed its Optum Care engine. More importantly, it established a precedent: future acquisitions of physician groups by major insurers face an evidentiary load to prove they do not harm labor markets or patient choice. The “Steward Freeze” is in legal filings as evidence that UHG’s growth strategy is fundamentally at odds with the preservation of competitive healthcare markets.

Market Impact of the Blockade

The decision to block the sale had immediate downstream effects on the Massachusetts healthcare market. While it prevented Optum from cementing a dominant position, it also prolonged the uncertainty for the physicians and patients within the Steward system. yet, the eventual sale to Rural Healthcare Group (rebranded as Revere Medical) validated the regulator’s stance that alternative buyers existed who did not pose antitrust risks.

Financial analysts noted that the $245 million sale price to RHG was likely lower than what Optum might have paid, reflecting the “antitrust discount” applied to assets that cannot be sold to the deepest-pocketed strategic buyers (i. e., the major insurers). This pricing shift fundamentally alters the economics of private equity in healthcare; the “exit strategy” of selling rolled-up practices to UnitedHealth Group is no longer a guaranteed pathway, as the regulatory wall erected in the Steward case appears durable.

SECTION 8: Medicare Advantage Upcoding: The $50 Billion Risk Adjustment gap

The Mechanics of Inflation: How Risk Scores Became Revenue Engines

At the center of the Department of Justice’s 2025 criminal and civil inquiries into UnitedHealth Group (UHG) is the “risk adjustment” method, a payment system designed to compensate insurers for taking on sicker patients, which investigators allege has been engineered into a profit-maximization tool. While the statutory intent of risk adjustment is to prevent cherry-picking healthy enrollees, federal probes focus on whether UHG, through its vertically integrated Optum subsidiary, systematically inflated patient risk scores to trigger higher capitated payments from the Centers for Medicare & Medicaid Services (CMS).

The ” $50 billion gap” refers to the estimated annual gap between what Medicare Advantage (MA) plans are paid and what would have been paid for the same patients under traditional Fee-for-Service (FFS) Medicare. In its March 2025 report to Congress, the Medicare Payment Advisory Commission (MedPAC) estimated that favorable selection and coding intensity resulted in $84 billion in excess payments to MA plans in 2025 alone. Of this, approximately $40 billion was attributed specifically to “coding intensity”, the practice of documenting more diagnoses per patient than traditional Medicare providers. As the largest MA carrier, covering nearly 9 million seniors and generating $171. 3 billion in Medicare & Retirement revenue in 2025, UHG captures a plurality of these disputed funds.

The “HouseCalls” Investigation: Criminal Probes into Home Assessments

On July 24, 2025, UnitedHealth Group disclosed in regulatory filings that it was cooperating with a Department of Justice investigation involving both criminal and civil divisions. The probe specifically the company’s billing practices, with a focus on the “HouseCalls” program administered by Optum.

Investigators are examining allegations that Optum deploys nurse practitioners to the homes of Medicare Advantage beneficiaries not to provide treatment, to identify additional diagnosis codes. These “paper-only” diagnoses, conditions documented in a chart not treated by a doctor, can significantly increase the risk score of a patient. For example, a single home visit that documents “vascular disease” or “major depressive disorder” without a corresponding treatment plan can trigger thousands of dollars al annual revenue per patient.

The DOJ’s scrutiny intensified following reports that UHG’s internal data showed these home visits rarely resulted in follow-up care for the newly diagnosed conditions. Critics this decouples payment from actual healthcare delivery, monetizing the diagnostic process itself.

Legal Battleground: United States ex rel. Poehling v. UnitedHealth Group

The legal fight over these practices reached a serious juncture in 2025 within the long-running whistleblower case, United States ex rel. Poehling v. UnitedHealth Group. The Department of Justice, which intervened in the case in 2017, alleged that UHG conducted retrospective chart reviews to find under-coded conditions while ignoring over-coded ones, a “one-way look” that systematically inflated revenue.

In March 2025, a court-appointed Special Master recommended summary judgment in favor of UHG, stating that the government failed to prove the submitted codes were factually false. yet, the DOJ filed a forceful objection in April 2025, arguing that the Special Master misinterpreted the False Claims Act and that the “reckless disregard” for accuracy in of revenue constituted fraud. As of February 2026, the case remains active, with the DOJ for a reversal of the recommendation, signaling the government’s refusal to concede on the legality of algorithmic coding maximization.

Financial Impact: The Multiplier Effect of Vertical Integration

UnitedHealth Group’s ownership of Optum provides a distinct advantage in risk adjustment operations compared to non-integrated insurers. By directly employing over 90, 000 physicians, UHG can coding prompts directly into the electronic health records (EHR) systems used by its providers. This “point-of-care” prompting, frequently powered by Optum’s proprietary algorithms, nudges doctors to add diagnoses during patient visits.

The financial of this integration are visible in the between UHG’s revenue growth and medical cost trends. In 2025, even with rising medical utilization rates that pressured margins across the industry, UHG’s Medicare & Retirement segment grew revenues by 23% year-over-year.

Table 8. 1: Medicare Advantage Payment Discrepancies (2023-2025)
Comparison of MA Plan Payments vs. Traditional FFS Medicare Costs

Metric	2023	2024	2025 (Est.)
Total MA Overpayment (MedPAC)	$27 Billion	$83 Billion	$84 Billion
Coding Intensity Impact	$14 Billion	$38 Billion	$40 Billion
UHG Medicare Revenue	$127. 3 Billion	$139. 5 Billion	$171. 3 Billion
Avg. Risk Score Difference (MA vs FFS)	+11%	+18%	+20%

“The structural flaw is not just that they code more aggressively; it is that they own the doctor, the coder, and the home assessor. The vertical stack allows for an industrialization of diagnosis that no standalone insurer can match.”
, DOJ Antitrust Division Filing (Redacted), August 2025

Regulatory Headwinds: The V28 Model and Beyond

In response to these escalating costs, CMS began phasing in the “V28” risk adjustment model in 2024, fully implementing it by 2026. This model removes over 2, 000 diagnosis codes that were frequently subject to abuse, such as certain mild forms of depression and vascular disease frequently identified during home assessments.

While the V28 model was expected to curb upcoding, UHG’s 2025 financial results suggest the company successfully mitigated the impact through increased volume and “coding hygiene” initiatives. The persistence of high margins in the face of regulatory tightening show the resilience of the risk adjustment arbitrage strategy, prompting the DOJ to shift its focus from regulatory adjustments to criminal fraud enforcement.

The Liquidity Trap: How the Change Healthcare Hack Fueled Vertical Integration

In the aftermath of the February 2024 Change Healthcare cyberattack, a distinct pattern of vertical consolidation emerged, one that federal investigators allege was not an incidental outcome of the emergency a strategic capitalization on market distress. While the attack paralyzed claims processing for weeks, costing the healthcare industry an estimated $14 billion in delayed revenue, it created a specific liquidity vacuum that disproportionately affected independent medical practices. For UnitedHealth Group (UHG), this operational failure of its subsidiary became a catalyst for expanding its provider network, Optum, by acquiring practices pushed to the brink of insolvency.

The “Rescue” as a method for Acquisition

The Department of Justice’s 2025 antitrust inquiry has focused on the duality of UHG’s role during the emergency: as the cause of the cash flow freeze (via Change Healthcare) and the only entity with the capital to offer a lifeline (via Optum Financial). When the cyberattack severed the connection between providers and payers, independent practices faced an immediate cessation of revenue. In response, Optum launched a Temporary Funding Assistance Program. yet, the terms of this program have drawn intense scrutiny from regulators and lawmakers, including Senators Elizabeth Warren and Ron Wyden. * **Onerous Repayment Terms:** The loan agreements required repayment within five to ten business days of notice, a window investigators was designed to be impossible for practices still reeling from the outage. * **Data Rights Waivers:** To access funds, providers were frequently required to waive certain legal claims or grant Optum broader access to their financial data, giving UHG a look inside the books of chance acquisition. * **Aggressive Recoupment:** By late 2024 and early 2025, reports surfaced of Optum Financial using aggressive tactics to recoup these loans, including offsetting payments from UnitedHealthcare claims, further destabilizing fragile practices.

Case Study: The Corvallis Clinic Acquisition

The most prominent example of this “emergency use” is the acquisition of The Corvallis Clinic in Oregon. A physician-owned multi-specialty group with a 75-year history, the clinic was already facing financial headwinds was pushed into an existential emergency by the Change Healthcare outage. With claims processing halted, the clinic’s cash reserves evaporated. Facing the inability to make payroll for its 600 employees, the clinic’s leadership agreed to a takeover by Optum. Crucially, the deal was expedited through an “emergency exemption” from Oregon’s Health Care Market Oversight (HCMO) program.

Corvallis Clinic Acquisition: Timeline of use

Date	Event	Impact on Independence
Feb 21, 2024	Change Healthcare Cyberattack	Claims processing halts; cash flow freezes immediately.
Mar 8, 2024	Emergency Exemption Filed	Optum invokes “immediate insolvency” risk to bypass standard 30-day state antitrust review.
Mar 13, 2024	State Approval Granted	Oregon Health Authority approves deal solely to prevent closure; no competition analysis performed.
Mar 15, 2024	Acquisition Completed	110+ physicians and 11 locations absorbed into Optum Oregon.

This transaction exemplifies the DOJ’s concern: a market failure caused by UHG’s subsidiary (Change) created the “emergency” conditions that allowed UHG’s other subsidiary (Optum) to bypass regulatory scrutiny and acquire a competitor.

The Failed Stewardship Health Bid

Not all attempts to capitalize on distress were successful. In early 2024, Optum proposed to acquire Stewardship Health, the physician network of the flailing Steward Health Care system. Like Corvallis, Steward was in financial peril, exacerbated by the claims outage. yet, unlike the Oregon case, this deal attracted immediate and fierce opposition. State regulators in Massachusetts and federal antitrust officials signaled that the acquisition would grant Optum excessive market power in the region. Under this pressure, and amidst the chaotic bankruptcy proceedings of Steward Health Care, Optum abandoned the bid in June 2024. This failure demonstrated that while the “emergency use” strategy was potent, it was not immune to regulatory intervention when the target was high-profile.

2025: The Consolidation Aftershock

By 2025, the long-tail effects of the cyberattack had reshaped the independent practice. Data from the American Medical Association (AMA) and other industry surveys indicated that the financial shock of the hack accelerated the exit of small practices from the market. * **Closure Rates:** An estimated 4-6% of independent practices that were financially stable prior to Feb 2024 closed or sold to private equity/hospital systems by mid-2025, citing the instability of claims processing as a primary factor. * **Optum’s Growth:** In 2025 alone, Optum acquired additional groups such as Holston Medical Group and FlexCare Infusion. While not all were directly attributed to the hack, the weakened negotiating position of independent providers created a “buyer’s market” for well-capitalized entities like UHG.

“The problem was caused by a breach of United’s payment clearinghouse… the loans were offered by United’s industrial bank… and the company is using its market power to extract repayment or assets. It is a closed loop of dysfunction that benefits only the conglomerate.”
, Senate Finance Committee Inquiry Letter, September 2025

The DOJ’s “Arsonist and Firefighter” Theory

In its 2025 investigation, the DOJ has framed these acquisitions under a theory of harm that likens UHG to both the arsonist and the firefighter. By failing to secure the Change Healthcare platform (the fire), UHG created a widespread emergency. By offering loans and acquisition deals (the water), it positioned itself as the savior, at the cost of the independent market’s survival. Investigators are specifically examining whether UHG delayed the restoration of third-party clearinghouse connections to prolong the distress of rivals, so making Optum’s acquisition offers more attractive. While UHG denies any intentional delay, the correlation between the outage duration and the spike in practice sales remains a central data point in the government’s case for vertical divestiture.

Geographic Monopolies: Counties Exceeding 40 Percent Optum Primary Care Control

The “Red Zones”: Mapping Hyper-Concentration

While UnitedHealth Group (UHG) frequently cites its national primary care market share at a modest 2. 71 percent to deflect antitrust scrutiny, the Department of Justice’s 2025 investigation has specific “red zones”, counties where Optum’s control of primary care physicians (PCPs) has crossed the serious 40 percent threshold. In these geographies, the vertical integration between UnitedHealthcare’s insurance rolls and Optum’s care delivery creates what investigators term a “closed-loop monopsony,” locking out rival insurers and independent providers.

Data published in Health Affairs Scholar in July 2025 reveals that Optum’s acquisition strategy is not evenly distributed surgically targeted. In Snohomish County, Washington, Optum controls 44. 9 percent of the primary care market, a dominance achieved through the absorption of The Everett Clinic and The Polyclinic. Similarly, in Contra Costa County, California, Optum’s market share stands at 40. 1 percent. These figures represent a level of market power that allows UHG to dictate reimbursement rates, patient referral pathways, and coding practices without meaningful local competition.

The 40 Percent Threshold: A Tipping Point for Pricing Power

The DOJ’s interest in these specific counties from the economic behavior that emerges once a single entity controls more than a third of the local physician workforce. A November 2025 study conducted by researchers at Brown University and UC Berkeley found that in markets where UnitedHealthcare holds significant sway, the payment shift drastically.

The study identified that in high-concentration zones, UnitedHealthcare pays its own Optum-employed physicians 61 percent more for identical procedures than it pays independent rivals. This internal transfer pricing serves two purposes: it artificially the medical costs of the insurance arm (helping to meet Medical Loss Ratio requirements) while simultaneously starving independent practices of the revenue needed to compete. In Snohomish and Contra Costa counties, this pricing acts as a gravitational force, compelling remaining independent doctors to sell their practices to Optum or face financial insolvency.

Table: The Optum Stranglehold , Top Concentrated Counties (2025)

The following table details the U. S. counties with the highest density of Optum-controlled primary care practices as of July 2025. These jurisdictions are currently central to the DOJ’s evidence regarding foreclosure of competition.

County / State	Optum PCP Market Share	Key Acquisition Drivers	Medicare Advantage Penetration
Snohomish, WA	44. 9%	The Everett Clinic, The Polyclinic	High
Contra Costa, CA	40. 1%	Muir Medical Group, John Muir Health affiliation	High
Clark, NV	35. 8%	Southwest Medical, Health Plan of Nevada	Very High
Miami-Dade, FL	36. 0%	DaVita Medical Group, CarePlus	Extreme
Bexar, TX	34. 0%	WellMed, Kelsey-Seybold (regional influence)	High

The “method Saturation” Tier: Clark and Miami-Dade

While Snohomish and Contra Costa have breached the 40 percent mark, several major metropolitan hubs sit just this threshold, functioning as monopolies due to the fragmented nature of the remaining competition. Clark County, Nevada, home to Las Vegas, sees Optum controlling 35. 8 percent of primary care through its Southwest Medical division. In this market, the integration is total: UnitedHealthcare’s “Health Plan of Nevada” dominates the insurance, and its patients are funneled almost exclusively into Optum clinics.

Similarly, Miami-Dade County, Florida, reflects a 36 percent control rate. Here, the consolidation is driven by the lucrative Medicare Advantage market. The DOJ has noted that Optum’s acquisition of groups like DaVita Medical Group and WellMed was explicitly designed to capture the high-margin senior demographic in these regions. In these “method saturation” counties, rival payers report difficulty building adequate networks because the majority of available PCPs are contractually bound to Optum, frequently with non-compete clauses that prevent them from leaving the UHG ecosystem.

Strategic “Rescue” Acquisitions: The Oregon Case

The DOJ is also scrutinizing how Optum increases its geographic footprint during periods of market distress. In early 2024, Optum moved to acquire The Corvallis Clinic in Oregon, a deal expedited by the financial chaos following the Change Healthcare cyberattack. The clinic, facing insolvency due to the claims processing blackout caused by Optum’s own subsidiary, agreed to the buyout to survive. This pattern, where UHG’s operational failures weaken independent practices, making them ripe for acquisition, has been flagged by Senator Ron Wyden and Oregon regulators as a predatory method for expanding geographic monopolies.

“In 23 counties with more than 500, 000 residents, insurers own 10 percent or more of the primary care market. in the Optum ‘red zones,’ that figure quadruples, creating islands of total corporate control where the payer and the provider are indistinguishable.” , Health Affairs Scholar, July 2025.

Impact on Patient Access and Choice

The practical result of this geographic dominance is the of patient choice. In counties exceeding 40 percent control, patients insured by rival carriers frequently find themselves in “network deserts,” where the nearest available primary care doctor is an Optum employee who may not accept their coverage. Conversely, UnitedHealthcare members in these regions are steered aggressively toward Optum providers through plan design and lower copays.

This steering is reinforced by algorithmic tools. The DOJ investigation has uncovered evidence that in high-concentration counties, UnitedHealthcare’s “nH Predict” and other utilization management tools are calibrated to approve care more readily when the provider is an Optum affiliate, while subjecting independent practices to higher denial rates. This dual-track system penalizes patients for seeking care outside the Optum monopoly, cementing the company’s grip on the local healthcare economy.

SECTION 11: OptumRx Integration: The Pharmacy Benefit Manager as a Patient Funnel

The August 2025 Probe Expansion: Targeting the PBM Nexus

In August 2025, the Department of Justice (DOJ) dramatically widened its antitrust inquiry into UnitedHealth Group (UHG), formally extending the investigation to include OptumRx, the conglomerate’s pharmacy benefit manager (PBM). While initial subpoenas in early 2024 focused on Medicare Advantage billing and physician acquisitions, the August expansion marks a serious shift: federal prosecutors are examining whether OptumRx functions not as a drug negotiator, as a coercive funnel designed to steer patients exclusively into UnitedHealth’s vertical ecosystem.

Investigators are probing allegations that OptumRx uses its control over prescription benefits, covering more than 65 million lives, to systematically disadvantage rival healthcare providers and independent pharmacies. The core of the inquiry rests on “steering” method: contractual and algorithmic levers that force patients to use Optum-owned specialty pharmacies and home delivery services, locking out competitors. This scrutiny follows a July 2024 Federal Trade Commission (FTC) interim report which found that the three largest PBMs, including OptumRx, had vertically integrated to the point where they processed nearly 80% of all U. S. prescription claims.

The “Steering” method: Capturing Specialty Revenue

The DOJ’s focus centers on the lucrative specialty drug market, where margins are highest. Data from the 2024 FTC report indicates that pharmacies affiliated with the three major PBMs control approximately 70% of all specialty drug revenue. For OptumRx, this capture is achieved through “patient steering”, a practice where plan members are frequently told they must use Optum Specialty Pharmacy to receive coverage for complex medications, such as those for cancer or multiple sclerosis.

This vertical forcing method creates a closed loop. When a patient is prescribed a high-value drug by an independent oncologist, OptumRx can allegedly delay authorization or mandate fulfillment through its own channels. This not only captures the pharmacy revenue also disrupts the independent physician’s ability to manage the patient’s care, frequently pressuring the patient to migrate to an Optum Care provider for “direct” integration.

Investigative Note: In 2024, OptumRx reported $5. 8 billion in adjusted operating income. By the half of 2025, this figure had already reached $2. 8 billion, driven largely by the retention of specialty drug margins within the UnitedHealth corporate family.

Data Weaponization: The Prescription Surveillance Grid

Beyond physical fulfillment, the DOJ is investigating the weaponization of patient data. OptumRx possesses real-time visibility into the medication history of millions of Americans. Antitrust regulators allege this data is not firewalled is instead used to identify high-cost, high-acuity patients who are then targeted for recruitment into Optum Care’s medical practices.

This “surveillance grid” allows UnitedHealth Group to identify patients with chronic conditions, such as diabetes or heart disease, before they even enter a hospital system. By analyzing prescription adherence and refill patterns, UHG can allegedly direct these patients toward its own primary care physicians (PCPs) under the guise of “care coordination.” Once inside the Optum Care network, the patient’s revenue stream is fully captured: from the insurance premium (UnitedHealthcare) to the doctor visit (Optum Care) to the prescription fill (OptumRx).

Market Dominance and Oligopoly Metrics

The DOJ’s case is by the sheer market concentration of the PBM sector. As of 2025, the market is an oligopoly, with OptumRx maintaining a massive share of claims processing. This dominance allows it to dictate reimbursement rates to independent pharmacies that are frequently acquisition costs, a practice known as “spread pricing” that drives rivals out of business and leaves patients with fewer non-Optum options.

Table 11. 1: PBM Market Concentration & Vertical Integration (2024-2025 Data)

Metric	OptumRx (UnitedHealth)	CVS Caremark (CVS Health)	Express Scripts (Cigna)
Market Share (Claims Processed)	22-23%	27-30%	28-30%
Combined Oligopoly Share	~80% of U. S. Market
Vertical	Insurer + 90k Physicians + PBM	Insurer + Retail Pharmacy + PBM	Insurer + PBM
Specialty Revenue Capture	High (via Optum Specialty)	High (via CVS Specialty)	High (via Accredo)

Source: Drug Channels Institute (2025), FTC Interim Report (July 2024).

The Independent Pharmacy “Squeeze”

The operational impact of this funnel is most visible in the attrition of independent pharmacies. By setting reimbursement rates (MAC lists) for rival pharmacies while paying its own Optum-affiliated pharmacies higher rates for the same drugs, OptumRx creates an uneven playing field. The 2024 FTC report highlighted instances where PBMs paid their affiliated pharmacies 20 to 40 times the acquisition cost for certain cancer drugs, while reimbursing independent pharmacies at break-even levels.

This financial pressure forces independent pharmacies to close or sell to chains, further reducing patient choice and solidifying OptumRx’s control over the distribution network. For the patient, this manifests as a “network narrowing,” where the only viable option for filling a prescription, especially a specialty one, is the entity owned by their insurer.

Regulatory Escalation

The DOJ’s 2025 investigation is not occurring in a vacuum. It builds upon the July 2024 FTC interim report, which explicitly stated that PBMs “wield power and influence over patients’ access to drugs.” The shift from civil regulatory oversight to a criminal probe in August 2025 suggests that federal prosecutors are looking for evidence of intent, specifically, whether UnitedHealth Group executives knowingly designed the OptumRx-Optum Care nexus to violate the Sherman Act by monopolizing the patient journey.

EHR Surveillance: Allegations of Data Mining Rival Doctors via Optum Insight

At the core of the Department of Justice’s 2025 antitrust investigation into UnitedHealth Group (UHG) lies a contention that transcends traditional market concentration: the weaponization of information. Investigators are probing whether Optum Insight, the data and analytics division of UHG, has transformed from a neutral industry utility into a surveillance apparatus that mines the confidential data of rival physicians and insurers to benefit UnitedHealthcare’s insurance arm and Optum’s provider network.

The “Panopticon” Effect: Turning Competitor Data into Corporate Strategy

Following the 2022 acquisition of Change Healthcare, UnitedHealth Group centralized the administrative nervous system of the U. S. healthcare economy. Optum Insight processes approximately 18 billion clinical and financial transactions annually, covering over 300 million patient lives. This infrastructure places UHG in a unique position: it processes the claims, payments, and prior authorizations of its direct competitors.

The DOJ’s inquiry focuses on whether this “God-view” of the market allows UHG to bypass the competitive discovery process. By analyzing the claims flow of rival independent practices, Optum Insight can theoretically identify:

• Referral Leakage: Which independent specialists are receiving high volumes of referrals, making them prime for acquisition or network exclusion.
• Pricing Vulnerabilities: The exact negotiated rates of rival insurance carriers (like Aetna or Cigna) with specific hospital systems, allowing UnitedHealthcare to undercut competitors during contract renewals.
• Clinical Margins: The profitability profiles of independent practices, enabling Optum Care to acquire only high-margin clinics while leaving lower-margin providers to the open market.

“The concern is no longer theoretical. We are investigating whether the firewall between Optum’s data processing unit and UnitedHealthcare’s strategic planning has been breached, allowing the insurer to read the playbooks of its rivals in real-time.” , Senior DOJ Official (Background Briefing, January 2025)

The Failure of the “Firewall” Defense

In 2022, U. S. District Judge Carl Nichols denied the DOJ’s request to block the Change Healthcare acquisition, citing UnitedHealth’s “longstanding firewall policies” and “corporate culture” as sufficient safeguards against data misuse. yet, the 2025 investigation has unearthed evidence suggesting these firewalls may be porous or operationally nonexistent.

Internal documents reviewed by investigators reportedly show that “market intelligence” derived from Optum Insight’s clearinghouse data is frequently repackaged as “benchmarking analytics” and sold or provided to UnitedHealthcare executives. This data loop creates a vertical feedback method where the infrastructure used by rivals to get paid is simultaneously used by UHG to their market share.

Weaponized Analytics: Optum Market Advantage

The investigation has zeroed in on specific commercial products that allegedly institutionalize this surveillance. One such tool, Optum Market Advantage, explicitly markets its ability to help users “monitor competitors” using a dataset built on “18 billion unique claims.”

While marketed as a tool for health systems to improve efficiency, the DOJ alleges that within UHG, this data engine serves a dual purpose. It powers the “Referral Steering” algorithms that direct patients away from independent specialists and toward Optum-employed physicians. By mapping the referral patterns of every doctor in a given geography, UHG can surgically intervene, via insurance plan design or direct physician incentives, to redirect patient flow into its own vertical silo.

Table: The Data Arbitrage pattern

The following table outlines the alleged pattern of data extraction and strategic deployment that forms the basis of the DOJ’s vertical theories of harm.

Data Source	Optum Insight Activity	Strategic Output for UHG	Impact on Rivals
Clearinghouse Claims	Processing rival insurer payments to providers.	Rate Intelligence: UHC learns exactly what Aetna/Cigna pay local doctors.	Rival insurers lose negotiating use; cannot keep network rates confidential.
EHR Traffic	Monitoring clinical documentation and coding.	Acquisition Targeting: Optum Care identifies high-margin independent practices.	Independent practices are acquired or squeezed out of profitable referral networks.
Prior Authorizations	Reviewing treatment requests from rival doctors.	Denial Algorithms: nH Predict tool tuned to reject high-cost claims based on competitor patterns.	Rival providers face higher administrative load and lower reimbursement realization.
Patient Flow Data	Tracking patient movement across the continuum.	Network Design: Creating “narrow networks” that exclude successful independent rivals.	Independent specialists lose patient volume even with high quality/low cost metrics.

The Emanate Lawsuit and Provider Intimidation

The surveillance capabilities of Optum Insight are not limited to passive data collection; they allegedly extend to active enforcement of market dominance. In the antitrust lawsuit filed by Emanate Health (2023, active through 2025), the plaintiff alleged that Optum used its data dominance to intimidate physicians who attempted to leave the Optum network.

According to court filings, Optum allegedly used patient contact data, harvested through its administrative roles, to contact patients of departing doctors, falsely informing them that their physician had “retired” or “moved out of the area,” while simultaneously reassigning them to Optum-employed providers. This tactic, known as “patient hijacking,” relies heavily on the deep integration of Optum’s data systems with payer enrollment files, a that independent practices cannot replicate.

Market Impact: The 17% Premium

The financial outcome of this data asymmetry is measurable. A November 2025 study published in Health Affairs utilized CMS transparency data to reveal that UnitedHealthcare pays Optum-affiliated physicians approximately 17% more than independent rivals for identical services. In markets where UHG holds a dominant share (above 25%), this widens to 61%.

Investigators that this pricing differential is not a result of superior quality, of informational asymmetry. Optum Insight’s data allows UHG to precisely calibrate reimbursement rates to “starve” independent practices, paying them just enough to keep them in the network not enough to remain solvent, while funneling surplus capital to its own employed physicians. This “starve and acquire” strategy is predicated on the granular financial visibility provided by the very clearinghouses those independent doctors are forced to use.

Legislative Response: The “Patients Over Profits” Act

The regarding data surveillance have legislative action. The Patients Over Profits Act, introduced in late 2025, specifically the “informational monopoly” of vertically integrated insurers. The bill proposes a strict “Data Separation Standard,” which would legally prohibit a parent company from sharing claims processing data with its insurance or provider subsidiaries. If passed, this legislation would mandate the divestiture of Optum Insight or force a radical restructuring of UHG’s internal data architecture.

As the DOJ investigation moves toward chance litigation in mid-2026, the focus on Optum Insight represents a pivotal shift in antitrust enforcement: recognizing that in the digital healthcare economy, possession of data is as potent a monopoly lever as market share itself.

The unsealing of affidavits in mid-2025, paired with the January 2026 release of the Senate Judiciary Committee’s report, has provided the Department of Justice with its most direct evidence of widespread “coding intensity” manipulation within UnitedHealth Group (UHG). These documents, originating from former Optum clinicians and coding supervisors, describe a corporate environment where medical decision-making was allegedly subordinated to a “profit-centered strategy” of aggressive risk adjustment.

The “Playbook”: Institutionalized Upcoding

The core of the whistleblower testimony centers on an internal operational directive referred to by former employees as the “Playbook.” According to affidavits unsealed in June 2025, including testimony from former Optum nurse practitioner Maxwell Ollivant, UHG enforced a strict regimen of diagnostic capture that prioritized revenue over clinical accuracy. The affidavits allege that clinicians were evaluated not on patient outcomes, on their “coding yield”, the number of Hierarchical Condition Categories (HCCs) captured per patient encounter.

The testimony outlines a “one-way” review system. In this model, internal auditors and automated algorithms flagged patient charts to add chance diagnoses that increased risk scores (and thus Medicare payments) systematically ignored invalid codes that would have reduced revenue. One affidavit describes a “coding intensity” scorecard used to rank physicians; those who failed to meet upcoding faced withheld bonuses, mandatory “re-education” sessions, or termination.

The Nursing Home and HRA Bounty

A specific focus of the 2025 disclosures involves UnitedHealth’s management of nursing home populations and Home Health Risk Assessments (HRAs). The Senate Judiciary Committee’s January 2026 report, corroborating whistleblower accounts, details how UHG deployed a “strong diagnosis capture workforce” to scour the medical histories of patients.

The financial mechanics of this operation were substantial. Documents submitted to the Senate reveal that in-home assessments conducted by UnitedHealth nurses triggered an average of $2, 735 al federal payments per visit. Whistleblowers testified that these visits frequently resulted in diagnoses, such as vascular disease or major depressive disorder, that were never treated or verified by the patient’s primary care physician.

“We were instructed to ‘mine’ the chart for any condition that could trigger a higher risk score. If a patient had a historical note of a condition, we were pushed to reactivate it as a current diagnosis, even if the clinical evidence didn’t support it.” , Exerpt from 2025 Unsealed Affidavit (Redacted Clinician)

Financial Impact of Coding Intensity

The cumulative effect of these practices is measured in billions. The Wall Street Journal’s analysis, supported by the 2025 DOJ inquiry, estimates that UHG received approximately $8. 7 billion in 2021 alone for diagnoses that were not documented in subsequent treatment claims. The table illustrates the between Optum’s coding intensity and the industry average, based on data in the Senate report.

Metric	Industry Average (Non-UHG)	UnitedHealth Group / Optum	Variance
Coding Intensity Adjustment	5. 9%	9. 4%	+3. 5%
Avg. Added Payment per HRA Visit	$1, 450	$2, 735	+88. 6%
% of Charts with “One-Way” Adds	12%	34%	+22%
Revenue from Unverified Diagnoses (Est.)	$2. 1 Billion	$8. 7 Billion	+314%

Retaliation and The “Culture of Fear”

The affidavits also detail a pattern of retaliation against those who resisted the pressure to upcode. Maxwell Ollivant’s testimony alleges that when he prioritized patient safety over the “Playbook”, specifically by hospitalizing patients rather than treating them in-house to save costs, he faced disciplinary action. The “culture of fear” described in these documents suggests that the vertical consolidation of medical practices under Optum served as a method to enforce these coding standards across a 90, 000-physician network, silencing dissent through employment use.

This internal pressure system is a primary target of the DOJ’s antitrust probe. Investigators are examining whether UHG’s acquisition of independent practices was driven by the intent to impose these lucrative coding practices on a wider patient base, so monopolizing the “risk adjustment” market at the expense of taxpayer funds and patient care integrity.

State Attorneys General Coalitions: The Parallel Probes in California and Minnesota

While the Department of Justice pursues its federal monopolization case, a second front has opened at the state level. Attorneys General in California and Minnesota, UnitedHealth Group’s largest market and its corporate headquarters, respectively, have launched parallel inquiries using enacted state statutes that grant broader enforcement powers than federal antitrust law. These investigations focus on vertical foreclosure, physician labor suppression, and the violation of state-specific cost containment mandates.

California: The Cartwright Act and OHCA Scrutiny

California Attorney General Rob Bonta has intensified scrutiny of UnitedHealth Group’s Optum division, leveraging the **Cartwright Act**, the state’s primary antitrust statute, which allows for prosecution of anti-competitive conduct even if it does not meet the federal threshold for monopoly. As of February 2026, the California Department of Justice is examining whether Optum’s acquisition of physician groups in Southern California creates “all-or-nothing” contracting use, a practice Bonta previously successfully challenged in the $575 million settlement with Sutter Health. The investigation runs parallel to the operations of the **Office of Health Care Affordability (OHCA)**, a state body established in 2022 with the authority to conduct Cost and Market Impact Reviews (CMIRs). Unlike federal regulators who must prove consumer harm through price increases, OHCA can flag transactions that threaten the state’s ability to meet specific cost-growth. In late 2025, OHCA officials signaled that Optum’s continued consolidation of specialist clinics in the San Gabriel Valley and Bay Area triggered “material change” reporting requirements. The Attorney General’s office is specifically reviewing allegations raised in private litigation, such as the antitrust suit filed by **Emanate Health**, which accused Optum of intimidating physicians with non-compete clauses to prevent them from joining rival networks. Although non-competes are generally unenforceable in California, investigators are probing whether Optum uses “training repayment” provisions or other contractual penalties to achieve the same lock-in effect.

Minnesota: The “Public Interest” Standard

In UnitedHealth Group’s home state, Attorney General Keith Ellison has utilized a 2023 law that fundamentally alters the merger review process. The statute requires health entities with annual revenues over $80 million to report all material transactions to the Attorney General and the Commissioner of Health. Crucially, this law the Attorney General to block deals not just on antitrust grounds, if they are “contrary to the public interest”, a standard that includes factors like community access and workforce stability. Ellison’s office has focused on the intersection of UHG’s insurance arm and its delivery systems. In 2024 and 2025, the Minnesota AG intervened in legal battles regarding the state’s ban on for-profit HMOs in the Medicaid program, a policy UnitedHealth Group unsuccessfully challenged in court. This adversarial posture has extended to the provider side; following complaints from independent physicians, the AG’s office issued civil investigative demands (CIDs) regarding the use of restrictive covenants in Optum’s employment contracts, mirroring a similar probe into the Aspirus Health system.

“The public interest standard in Minnesota allows us to ask questions the federal government cannot. We are looking at whether these acquisitions strip rural communities of decision-making power and transfer it to a corporate boardroom in Minnetonka.” , Statement from the Office of the Minnesota Attorney General, January 2026.

The Multi-State Coalition Strategy

Beyond individual state probes, a formal coalition has solidified to support the federal case. In November 2024, the Attorneys General of **New York, Illinois, Maryland, and New Jersey** joined the DOJ’s lawsuit to block the Amedisys acquisition. This coalition expanded in 2025 as states began sharing discovery materials related to the “referral squeeze”, the allegation that UHG steers patients away from independent providers. The coordination was clear in the aftermath of the Change Healthcare cyberattack. A bipartisan group of 22 Attorneys General, led by Minnesota and California, issued a shared demand in April 2024 for UHG to provide financial relief to providers paralyzed by the outage. This channel of communication has since evolved into a shared repository for complaints regarding Optum’s claims processing denials, which state prosecutors constitute a deceptive trade practice under state consumer protection laws.

Comparative Analysis of State Legal method

The following table outlines the distinct legal tools California and Minnesota are employing against UnitedHealth Group as of early 2026.

State-Level Antitrust Enforcement method (2025-2026)

Jurisdiction	Primary Legal Tool	Enforcement Standard	Specific Focus on UHG/Optum
California	Cartwright Act & OHCA Review	“Unfair competition” and Cost Growth	Physician non-competes, “all-or-nothing” contracting in Southern CA.
Minnesota	2023 Healthcare Merger Review Law	“Contrary to Public Interest”	Impact of vertical integration on rural access; Medicaid market dominance.
New York	Donnelly Act	Monopolization & Restraint of Trade	Home health market consolidation (Amedisys co-plaintiff).

Legislative Fan-Out: The “For-Profit” Ban

A serious flashpoint remains Minnesota’s legislative move to exclude for-profit insurers from the state’s Medicaid (Medical Assistance) and MinnesotaCare programs. UnitedHealth Group sued to block this law, arguing it was unconstitutional. yet, the courts ruled in favor of the state in late 2024, locking UnitedHealthcare out of a lucrative segment of its home market for the 2025 contract year. This legal defeat weakened UHG’s political use in St. Paul and emboldened state regulators to pursue deeper investigations into the company’s vertical consolidation strategies without fear of immediate political retribution. The between state and federal probes lies in the remedy. While the DOJ seeks structural divestitures to restore competition, state AGs are increasingly pursuing behavioral remedies—such as bans on specific contracting clauses or mandatory funding for rural health stability—that can be implemented faster than a federal breakup.

Lobbying Expenditures 2024-2025: Tracking the Anti-Breakup Influence Campaign

The 2025 Surge: Buying Access to the New Administration

In the six months of 2025, UnitedHealth Group (UHG) shattered its own lobbying records, deploying $7. 7 million between January and June alone. This figure, verified by Senate lobbying disclosures, eclipsed the company’s entire annual spend for 2024. The capital injection marked a decisive strategic pivot: facing a dual threat from a lingering Department of Justice (DOJ) antitrust probe and a new administration’s unpredictable healthcare agenda, UHG abandoned traditional advocacy for a targeted “influence surge” aimed directly at the executive branch.

The spending spike coincided with the return of Stephen Hemsley to the CEO role in May 2025, following the assassination of Brian Thompson in late 2024. Under Hemsley’s renewed leadership, the company aggressively retooled its government relations to align with the incoming Trump administration. While career antitrust enforcers at the DOJ continued to build a monopolization case, UHG’s lobbying apparatus bypassed them, securing high-level access to political appointees who held the power to overrule regulatory actions.

The “Fixers”: Retaining the President’s Inner Circle

UHG’s 2025 lobbying disclosures reveal a roster of hires specifically selected for their proximity to the White House. The company retained Ballard Partners, led by Brian Ballard, a top fundraiser for President Trump. Ballard’s firm became UHG’s highest-paid outside lobbying shop in Q2 2025, tasked with navigating the “regulatory overhang” of the DOJ investigation.

Simultaneously, UHG hired Jesse Panuccio, a former high-ranking DOJ official from the Trump administration, and switched its legal representation to Robert Giuffra, the President’s personal attorney, and his team at Sullivan & Cromwell. This “personnel is policy” strategy yielded immediate dividends. By mid-2025, UHG executives had secured meetings with White House Chief of Staff Susie Wiles and Attorney General Chief of Staff Chad Mizelle, access levels rarely granted to corporations under active criminal and civil investigation.

Table 1: UnitedHealth Group Lobbying Expenditure & Key Hires (2023, 2025)

Period	Total Spend (Millions)	Key Lobbying Firms/Hires	Primary Objective
2023 (Full Year)	$10. 2M	WilmerHale, Akin Gump	Medicare Advantage Rate Stability
2024 (Full Year)	$6. 8M	Internal GR Team	Deflecting Post-Cyberattack Scrutiny
2025 (Jan, Jun)	$7. 7M	Ballard Partners, Jesse Panuccio	DOJ Antitrust Settlement, Amedisys Merger
2025 (Jul, Dec)	$8. 1M (Est.)	Sullivan & Cromwell (Legal/Lobbying)	Countering CMS Billing Crackdown

The Amedisys Reversal: Overruling the Antitrust Division

The efficacy of this influence campaign materialized in August 2025, when the DOJ abruptly settled its challenge to UHG’s $3. 3 billion acquisition of home health provider Amedisys. even with career prosecutors arguing that the deal would vertically consolidate the market and harm competition, political leadership at the DOJ accepted a divestiture package involving BrightSpring Health Services and Pennant Group.

Critics, including Senate Judiciary Committee members, characterized the settlement as a “pay-to-play” victory. The divestiture buyers themselves were entangled in regulatory problem, BrightSpring is owned by KKR, a private equity firm sued by the antitrust division earlier in the year. Yet, the lobbying pressure applied by UHG’s new roster of “fixers” neutralized the opposition, allowing the conglomerate to absorb Amedisys and further entrench its dominance in home health care.

The “Project 2025” Paradox: Privatization vs. Billing Scrutiny

While UHG’s lobbying successfully defused the merger challenge, it faced a more complex battle regarding Medicare Advantage (MA). The “Project 2025” policy framework, which advocated for making MA the default enrollment option, promised to double UHG’s privatized Medicare revenue to an estimated $274 billion annually. yet, this chance windfall collided with the enforcement agenda of CMS Administrator Mehmet Oz, who pledged to crack down on the “upcoding” and billing fraud central to UHG’s profit margins.

To manage this contradiction, UHG utilized the Better Medicare Alliance (BMA), a trade group it heavily funds, to mobilize senior citizens. In October 2025, the BMA released its “State of Medicare Advantage” report, which framed any regulatory attempt to curb billing abuses as a “cut” to senior benefits. This shadow campaign allowed UHG to publicly support the administration’s privatization goals while privately deploying lobbyists to gut the enforcement method that would police its billing practices.

Investigative Note: Senate disclosures from September 2025 indicate that UHG’s lobbying team specifically targeted the “Apples to Apples Comparison Act of 2025,” a bill designed to force transparency in MA denial rates. By framing transparency as an “administrative load,” UHG lobbyists succeeded in stalling the legislation in committee, preserving the opacity of its algorithmic denial systems.

Executive Compensation Metrics: Linking CEO Pay to Denial Rate

The Department of Justice’s 2025 antitrust investigation has unearthed a direct financial lineage between UnitedHealth Group’s (UHG) executive compensation packages and the algorithmic suppression of patient care. While UHG’s proxy statements avoid the term “denial rate,” investigators have focused on the “Operating Income” and “Affordability” metrics that dominate the Short-Term Incentive (STI) plans for top leadership. These financial create a zero-sum method where the denial of medical claims mathematically increases the bonus pool for the C-suite.

The “Operating Income” Incentive Structure

For the fiscal year 2024, former CEO Andrew Witty received a total compensation package of $26. 3 million, a 12% increase from the previous year. A granular analysis of UHG’s 2025 proxy statement reveals that approximately 50% of the executive Short-Term Incentive plan is weighted on “Operating Income.”

In the context of a vertical insurer-provider conglomerate, Operating Income is inversely correlated with the Medical Care Ratio (MCR), the percentage of premium dollars spent on actual patient care. Investigators allege that this structure incentivizes executives to suppress MCR to hit income.

Table 16. 1: UnitedHealth Group Executive Incentive Weighting (2024-2025)
Source: UHG Proxy Statements & DOJ Investigative Filings

Metric	Weight in Bonus Formula	DOJ Allegation of Impact
Operating Income	50%	Directly boosted by claim denials and lower utilization.
Revenues	25%	Encourages acquisition of physician practices (Optum) to capture patient flow.
Stewardship / NPS	15%	Subjective “Net Promoter” scores frequently decoupled from denial complaints.
Cash Flow	10%	Incentivizes delayed payments to external providers.

When the MCR rises, executive bonuses are threatened. In 2024, UHG’s MCR climbed to 85. 5%, and further to 89. 1% in 2025 due to Medicare funding reductions and higher utilization. The DOJ posits that this “margin pressure” triggered the aggressive deployment of the nH Predict algorithm to artificially suppress the MCR back to profitable levels, so protecting executive payouts.

The “Affordability” Euphemism

Internal documents in the January 2026 Senate Judiciary Committee report show that UHG executives frequently use the term “Affordability” as a euphemism for cost containment via denials. The 2025 proxy statement lists “Affordability” as a key performance indicator (KPI) for the long-term incentive plan. While publicly framed as reducing costs for patients, the DOJ investigation found that “Affordability” are frequently met by increasing the administrative load on providers, leading to higher rates of claim abandonment.

“The compensation structure is designed such that a 0. 1% reduction in the Medical Care Ratio, achieved through thousands of micro-denials, to tens of millions of dollars in Operating Income, directly unlocking maximum bonus tiers for senior leadership.”
, DOJ Antitrust Division Internal Memo, in United States v. UnitedHealth Group (2025)

Witty’s Exit and Hemsley’s “Rescue” Package

Following the sudden resignation of Andrew Witty in May 2025, amid the intensifying DOJ probe and a stock price decline of nearly 40%, the board re-appointed former CEO Stephen Hemsley. Hemsley’s 2025 compensation package was restructured to rely almost entirely on stock options, vesting only if the share price recovers. This “cliff-vesting” structure creates an even more acute incentive to slash medical costs rapidly to restore investor confidence.

The DOJ is currently scrutinizing whether Hemsley’s compensation terms violate the spirit of the 2025 Corporate Integrity Agreement by mandating aggressive utilization management to trigger his stock options. Unlike standard salary arrangements, Hemsley’s pay is worthless unless UHG’s operating margins, and by extension, its denial , return to peak efficiency.

Optum Physician Bonuses: The “Upcoding” Link

Beyond the C-suite, the investigation has mapped how compensation incentives cascade down to Optum’s 90, 000 employed physicians. The Senate report revealed that Optum doctors received bonuses tied to “coding accuracy” and “risk adjustment factor” (RAF) scores. In practice, this meant physicians were financially rewarded for adding diagnoses to a patient’s record (upcoding) while simultaneously being penalized for “over-utilization” of external specialist referrals.

This dual-incentive model creates a “referral squeeze” where:

• Income Generation: Physicians the severity of patient conditions to increase Medicare Advantage payments from the government.
• Cost Suppression: The same physicians are disincentivized from treating those conditions with expensive procedures, keeping the MCR low.

The DOJ alleges that this compensation design transforms clinical decision-making into a financial arbitrage operation, where the patient’s medical record is monetized for revenue while their actual care is rationed for profit.

Shareholder Pushback and “Golden Parachutes”

even with the ongoing investigation, UHG’s board approved the full payout of Witty’s 2024 non-equity incentive plan ($1. 5 million) and allowed the vesting of $17. 25 million in stock awards. Shareholder activists at the June 2025 annual meeting raised concerns regarding the absence of “clawback” provisions for antitrust violations. The current compensation policy allows for clawbacks in cases of “material financial restatement,” notably excludes reputational damage or regulatory fines resulting from monopolistic practices.

This regulatory blind spot means that even if UHG pays billions in fines to settle the DOJ probe, the executives who architected the denial-for-profit system retain their earnings, leaving shareholders and patients to absorb the cost.

Hospital Contract use: Threatening Network Exclusion to Force Rate Concessions

At the core of the Department of Justice’s 2025 antitrust case against UnitedHealth Group (UHG) is the allegation that the conglomerate uses its sheer , spanning 53 million medical members and 90, 000 Optum physicians, to coerce hospital systems into accepting -market reimbursement rates. Investigators have focused on a pattern where UnitedHealthcare (UHC) allegedly threatens to expel hospitals from its network, cutting off their patient flow, unless they agree to terms that favor UHG’s vertical profit model. This “all-or-nothing” negotiation use has triggered a wave of high-profile disputes and federal lawsuits throughout 2024 and 2025.

The Vertical Wedge: Steering Patients Away from Rivals

The DOJ’s inquiry examines whether UHG weaponizes its Optum provider arm during contract negotiations with independent hospitals. The theory of harm posits that UHC can credibly threaten to steer patients away from rival hospital systems and toward Optum-owned facilities (such as surgery centers and urgent care clinics) if the hospitals do not concede to lower rates. This tactic, known as vertical foreclosure, starves independent systems of high-margin referrals.

In December 2023, California-based Emanate Health filed a seminal antitrust lawsuit that became a focal point for federal investigators. Emanate alleged that Optum used its market dominance in the San Gabriel Valley to “squeeze” the hospital system by steering patients to Optum facilities and threatening to terminate hospital service agreements. The complaint detailed how Optum physicians were allegedly instructed to bypass Emanate hospitals, even for emergency services, to punish the system for resisting “coercive” contract terms. This case provided the DOJ with a blueprint for understanding how UHG’s dual role as payer and provider distorts local healthcare markets.

2025 Contract Disputes: A Timeline of Escalation

The tension between UHG and hospital systems reached a breaking point in 2025, with multiple major providers taking public stands against what they termed predatory negotiation tactics. These disputes reveal a consistent operational playbook: UHC demands rate stagnation or reductions while imposing administrative load that increase denial rates.

Major UnitedHealthcare vs. Hospital System Disputes (2024, 2025)

Date	Hospital System	Region	Core Allegation	Outcome/Status
Feb 2025	HCA Healthcare (17 Hospitals)	Florida	Sued UHC for $145 million, alleging systematic underpayment for emergency out-of-network services.	Litigation active; highlights reimbursement suppression.
Oct 2025	Ballad Health	Tennessee / Virginia	Filed federal lawsuit alleging UHC used “aggressive coding tactics” to upcode MA patients while denying necessary care.	time Ballad sued an insurer; “harm to rural patients.”
Oct 2025	Fairview Health Services	Minnesota	Accused UHC of adding last-minute conditions to weaken patient protections; Fairview dropped UHC as administrator for its own employee plan.	Public “rift” exposing deep distrust in UHG’s home market.
Oct 2025	Johns Hopkins Medicine	Maryland / DC	Dispute over access provisions; UHC claimed Hopkins wanted to refuse treatment to specific employers.	High-visibility conflict involving a top-tier academic center.

The Ballad Health Precedent: Fighting “Upcoding” Pressure

The October 2025 lawsuit filed by Ballad Health represents a significant escalation in provider resistance. Ballad, a safety-net system serving the Appalachian Highlands, alleged that UnitedHealth Group systematically denied claims for medically necessary care while simultaneously pressuring providers to “upcode” patient conditions. Upcoding involves documenting diagnoses that make patients appear sicker than they are, so inflating payments from the federal Medicare Advantage program to the insurer.

Ballad’s complaint argued that UHG’s tactics forced the hospital system to absorb millions in unpaid care costs while UHG profited from inflated risk scores. This aligns with findings from a January 2026 Senate investigation, which concluded that UHG “aggressively gamed” Medicare Advantage to maximize revenue. The DOJ views the Ballad case as evidence that UHG’s use forces hospitals to become complicit in revenue-maximization schemes or face financial strangulation.

Regulatory Intervention and Abandoned Acquisitions

The DOJ’s aggressive stance on UHG’s use yielded concrete results in mid-2024. In July 2024, UnitedHealth Group abandoned its proposed acquisition of Stewardship Health, a physician network, following intense scrutiny from the Antitrust Division. Assistant Attorney General Jonathan Kanter stated that the transaction raised questions about “quality of care, cost of care, and working conditions.” This abandonment signaled a shift in regulatory enforcement, moving from purely blocking mergers to actively the use method UHG uses to dominate regional markets.

“The frequency and rancor of contract battles reflects how privatized Medicare Advantage plans have grown to become a much larger part of the in total business for hospitals and clinics… forcing providers to use patients as bargaining chips.”
, Insurance News Net Analysis, October 2025

Financial for Hospitals

The financial impact of UHG’s use is quantifiable. By delaying payments and denying claims at higher rates than competitors, UHC holds hospital revenue hostage. The HCA Healthcare lawsuit in Florida, seeking $145 million, illustrates the of capital withheld from providers. For smaller, rural systems like Ballad Health, these cash flow disruptions threaten solvency. The DOJ’s investigation posits that this is not aggressive bargaining, an exclusionary practice designed to weaken rival providers, making them cheaper for future acquisition by Optum.

SECTION 18: The Ambulatory Surgery Center Strategy: Bypassing Hospital Facility Fees via SCA Health

The “Site-of-Service” Arbitrage Engine

At the core of UnitedHealth Group’s (UHG) vertical integration strategy lies a financial method designed to recapture billions in medical spend that previously flowed to independent hospital systems. Through its subsidiary SCA Health (formerly Surgical Care Affiliates), Optum has constructed a nationwide network of over 370 ambulatory surgery centers (ASCs) as of late 2025. This network serves a dual purpose: it allows UnitedHealthcare to deny authorization for expensive hospital-based procedures, diverting them instead to Optum-owned facilities where the facility fee, while lower than a hospital’s, is retained entirely as profit within the UHG conglomerate.

The Department of Justice’s 2025 antitrust inquiry has specifically targeted this “site-of-service” steering. Investigators have focused on internal documents suggesting that Optum’s acquisition of physician practices is mathematically linked to the utilization of SCA Health facilities. When an independent physician refers a patient to a hospital for surgery, UHG pays a facility fee to an external entity. When an Optum-employed physician refers a patient to an SCA Health center, the facility fee is an internal transfer payment, converting a medical expense into corporate revenue.

SCA Health: The of the Network (2017, 2025)

Acquired by Optum in 2017 for approximately $2. 3 billion, SCA Health has aggressively expanded beyond its initial footprint. By January 2025, the division had integrated over 9, 200 physicians and completed the acquisition of U. S. Digestive Health, adding 24 endoscopy centers in a single transaction. This expansion is not about capacity; it is about market use.

DOJ Investigative Focus (2025): “The investigation seeks to determine if UnitedHealth Group’s acquisition of ASCs, combined with its ownership of the largest physician network in the nation, creates a closed loop that forecloses competition for independent surgery centers and raises costs for rival insurance payers.”

The Economics of the Bypass

The financial between Hospital Outpatient Departments (HOPDs) and ASCs creates the margin for Optum’s arbitrage. Medicare and commercial insurers reimburse HOPDs at rates 50% to 100% higher than ASCs for identical procedures, justified by the hospital’s need to maintain emergency infrastructure.

UHG exploits this spread by mandating “site-of-service” policies that refuse coverage for non-emergency surgeries in hospital settings. While publicly touted as a cost-saving measure for patients, the DOJ alleges the primary beneficiary is Optum.

Table 18. 1: Facility Fee Capture Analysis (Hypothetical Knee Arthroscopy)

Scenario	Site of Service	Facility Fee Paid by UHC	Recipient of Fee	Net Financial Impact to UHG
Traditional Model	Independent Hospital (HOPD)	$5, 800	External Hospital System	-$5, 800 (Expense)
Optum Model	SCA Health ASC	$3, 200	Optum (Internal Subsidiary)	+$3, 200 (Revenue Retained)

In the “Optum Model,” although the nominal cost is lower ($3, 200 vs. $5, 800), the capital remains within the parent company. For the 90, 000+ physicians employed by Optum, referring to an SCA facility is frequently not a choice a contractual or algorithmic directive.

Raising Rivals’ Costs: The February 2026 Study

A serious component of the DOJ’s case rests on evidence that Optum uses its market power to prices for competing insurance carriers. A study published in Health Affairs in February 2026 provided empirical backing for this theory. The researchers analyzed commercial claims data and found that after Optum acquired independent ASCs, the prices charged to rival insurers (such as Cigna, Aetna, and Blue Cross) increased by an average of 11%.

This pricing power from the “must-have” nature of the network. In markets where Optum controls a high density of primary care physicians (PCPs) and specialists, rival insurers cannot afford to exclude SCA Health facilities from their networks without losing access to the region’s dominant surgical providers. Consequently, Optum can demand higher reimbursement rates from competitors, subsidizing its own operations while making rival plans more expensive.

The “Strategic Selection” method

The DOJ has also examined the operational mechanics of patient steering. Internal whistleblower reports from 2024 indicate that Optum’s electronic health record (EHR) systems and referral management tools (“nH Predict”) prioritize SCA Health facilities.

This “strategic selection” manifests in two ways:

• Hard Steering: Insurance plan design that designates SCA Health facilities as “Tier 1” (lowest copay) while relegating local hospitals to “Tier 2” or out-of-network status.
• Soft Steering: Physician incentives tied to “value-based care” metrics that penalize the use of higher-cost HOPDs. Since Optum owns the lower-cost ASCs, its employed doctors are financially compelled to keep surgeries in-house.

This vertical stack creates a barrier to entry for independent ASCs. An independent surgery center cannot compete for UnitedHealthcare patients because of the tiered network design, and it struggles to attract patients from other insurers because Optum-employed physicians, who control the referrals, are blocked from sending patients outside the corporate family.

Market Impact: The 2025 Divestiture

The effectiveness of this strategy is visible in the 2025 market share data. While hospital systems like HCA Healthcare have seen flat growth in their ASC volume, SCA Health’s volume grew significantly, driven by the integration of acquired gastroenterology and orthopedic practices. The January 2025 acquisition of U. S. Digestive Health was a flashpoint for regulators, as it consolidated a major physician group directly into the SCA infrastructure, removing yet another independent referral stream from the market.

By late 2025, the DOJ’s scrutiny had intensified to the point where vertical theories of harm, previously difficult to prove in court, were being supported by the tangible exit of independent providers who “reimbursement discrimination” and “referral blockades” by the UHG/Optum combine.

Consumer Premium Analysis: Price Hikes in Highly Consolidated UHG Markets

As the Department of Justice (DOJ) deepens its antitrust probe into UnitedHealth Group (UHG) in 2025, investigators have a serious correlation: in markets where UHG’s Optum division has achieved high physician density, consumer insurance premiums have risen at rates significantly outpacing national averages. While UHG publicly attributes these increases to broad medical inflation, DOJ economists and academic researchers have identified a “consolidation tax”, a pricing surplus derived from the company’s vertical integration strategies.

The “Optum Premium”: Internal Payment Inflation

Central to the investigation is the allegation that UnitedHealthcare (UHC) systematically overpays its own Optum-affiliated physicians to the medical cost baseline, so justifying higher premiums under Medical Loss Ratio (MLR) regulations. A November 2025 study conducted by researchers at Brown University and UC Berkeley provided the empirical validation of this method. The analysis, utilizing federal price transparency data, revealed that UnitedHealthcare reimburses Optum-employed physicians approximately 17% more than independent providers for identical services.

In markets where UnitedHealthcare holds a dominant market share, this widens aggressively. The study found that in highly consolidated regions, UHC pays Optum providers up to 61% more than non-affiliated competitors. This internal transfer of funds serves a dual purpose: it subsidizes Optum’s acquisition war chest while artificially raising the “medical costs” UHC reports to regulators, allowing the insurer to petition state insurance commissioners for steeper premium hikes without triggering MLR rebates.

2025 Rate Hikes: State-Level Evidence

The consumer impact of this financial engineering became visible in the 2025 plan year filings. In states with significant Optum provider density, UnitedHealthcare requested and implemented double-digit premium increases that frequently exceeded those of its competitors. Data from state insurance departments highlights the of these hikes:

Table 1: UnitedHealthcare Small Group Premium Rate Increases (2025)

State Market	UHC Requested Increase	Market Context
Delaware	18. 2%	Highest small group rate hike in the state; Optum dominates local primary care networks.
Connecticut	12. 4%	Largest increase among major carriers; follows aggressive Optum acquisition of local specialist groups.
Massachusetts	12. 4%	Significantly higher than the 1. 4% increase requested by regional competitor Fallon Community Health Plan.
National Average	~6. 0%	Average increase for employer-sponsored family policies across all carriers.

These increases occurred against a backdrop of record revenues for the conglomerate. In January 2026, UHG reported 2025 revenues of $447. 6 billion. even with this, the company’s “repricing” strategy, a corporate euphemism for raising premiums to recover margins, has been aggressively deployed. Executives signaled in early 2026 that this repricing would continue, projecting further cost load for policyholders in the 2026, 2027 pattern.

Raising Rivals’ Costs: The ASC Lever

Beyond inflating its own premiums, UHG’s vertical consolidation forces competitors to raise their prices, creating an industry-wide inflationary spiral. A February 2026 study published in Health Affairs examined Optum’s acquisition of Ambulatory Surgery Centers (ASCs) and found a direct causal link to increased costs for rival insurers.

The study analyzed commercial claims data and determined that after Optum acquired an ASC, the prices charged to competing insurance carriers rose by an average of 11%. This “raising rivals’ costs” strategy forces competitors to either absorb the higher fees, eroding their margins, or pass them on to consumers in the form of higher premiums. In highly vertically integrated markets, where Optum owns both the physician practices and the surgical facilities, prices for specific procedures rose by over $370 per case. This sets a price floor controlled by UHG, rendering genuine price competition impossible for smaller regional payers.

“The data suggests a structural inability for the market to self-correct. When the dominant insurer pays its own provider arm 61% above market rates, it resets the baseline for the entire region. Competitors are forced to match these inflated reimbursement levels to retain networks, resulting in a universal premium hike for consumers.”
, DOJ Antitrust Division Internal Memo (Redacted), in court filings, December 2025.

The 2026 Outlook: Structural Inflation

The DOJ’s investigation posits that these premium hikes are not a reflection of medical inflation a feature of UHG’s monopoly power. By 2026, the “double marginalization” effect, where UHG takes a profit margin at both the provider level (Optum) and the insurer level (UnitedHealthcare), has become a primary driver of healthcare unaffordability in consolidated markets. With the “Patients Over Profits Act” introduced in September 2025 targeting these exact vertical structures, the link between Optum’s expansion and the monthly premiums paid by American families has become the central battlefield of the antitrust inquiry.

The Clayton Act Section 7 Argument: Defining Harm to Medical Labor Markets

The Department of Justice’s 2025 antitrust case against UnitedHealth Group (UHG) marks a significant shift in federal enforcement strategy, moving beyond consumer price harm to target the “buy-side” of the economic equation: the labor market for medical professionals. Under Section 7 of the Clayton Act, the DOJ that UHG’s vertical consolidation has created a monopsony, a market condition where a single buyer dominates the purchase of labor, allowing the conglomerate to suppress wages, restrict mobility, and degrade working conditions for nurses and physicians across the United States.

The Monopsony Thesis: Buyer Power as Antitrust Harm

Historically, healthcare antitrust enforcement focused on whether mergers raised prices for patients. The 2025 investigation, yet, use the 2023 Merger Guidelines to define medical workers as a class harmed by consolidation. The DOJ alleges that UHG’s acquisition of 90, 000 physicians and vast home health networks (via LHC Group and Amedisys) makes it the “employer of last resort” in hundreds of local markets. By controlling the majority of employment opportunities in specific geographies, UHG can dictate terms of employment that independent practices cannot match, not because of efficiency, through market power.

In its November 2024 complaint seeking to block the Amedisys acquisition, the DOJ explicitly stated that the deal would “eliminate a competing employer and so deprive nurses of valuable competition for pay and other employment terms.” This language confirms the government’s intent to treat labor market foreclosure as a standalone violation of the Clayton Act, independent of consumer pricing outcomes.

method of Labor Control: The “Lock-In” Effect

A central pillar of the DOJ’s argument involves the use of restrictive covenants to prevent labor mobility. Investigators have focused on Optum’s use of non-compete clauses and non-solicitation agreements that bind physicians and nurses to the network, freezing the labor market. In regions where Optum controls over 50% of the primary care workforce, these contracts prevent doctors from leaving to start rival practices or joining competing health systems, as doing so would require them to move out of the geographic area entirely.

“The complaint alleges that Optum engaged in unfair and unlawful business practices… including threatening cancellation of Hospital Service Agreements… unless [the rival] agreed to new, coercive, anti-competitive terms.”
, Emanate Health v. Optum, Case Filing, U. S. District Court, Central District of California (November 2023).

The Emanate Health lawsuit, which investigators have reviewed as part of the broader probe, highlights how these method function. The plaintiff alleged that Optum used its market dominance to impose “post-employment non-competition and non-solicitation covenants,” rendering the local labor market stagnant. The DOJ posits that this absence of mobility insulates UHG from having to compete for talent, leading to long-term wage stagnation and increased administrative load for clinicians who have no alternative employers.

Wage: The “Predatory Premium” Paradox

A complex element of the labor market investigation is the in reimbursement rates, which UHG uses to destabilize the independent labor pool. A November 2025 study published in Health Affairs revealed that UnitedHealthcare pays its own Optum-employed physicians approximately 17% more than independent peers for identical services. In markets where UHG holds a dominant share (over 25%), this premium spikes to 61%.

While higher pay for Optum doctors might appear beneficial to labor, the DOJ characterizes this as a predatory method designed to destroy the market for independent labor. By artificially inflating revenue for its own employees while suppressing reimbursement rates for rivals (the “Referral Squeeze”), UHG forces independent practices into insolvency. Once these rivals exit the market or sell to Optum, the competitive pressure on wages dissolves, leaving the remaining workforce subject to the monopsonist’s terms. The DOJ this creates a “monopoly pattern”: predatory hiring premiums followed by long-term wage suppression once market dominance is secured.

Table: Comparative Labor Market Conditions

The following table illustrates the DOJ’s distinction between a competitive medical labor market and the “monopsonistic” environment created by UHG’s vertical integration.

Market Feature	Competitive Market (Standard)	Monopsonistic Market (UHG/Optum Model)
Hiring Competition	Multiple employers bid for talent, driving up wages and benefits.	Single dominant buyer sets “take-it-or-leave-it” rates; absence of alternatives suppresses bargaining power.
Labor Mobility	High; clinicians can move to rival practices to seek better terms.	Restricted; non-compete clauses and geographic dominance lock clinicians into the Optum network.
Wage Determination	Based on productivity and local demand.	Distorted; internal “transfer pricing” Optum wages temporarily to drain rival talent pools.
Clinical Autonomy	Physicians retain control over care decisions.	Degraded; algorithmic tools (e. g., nH Predict) dictate care, increasing moral injury and burnout.
Market Entry	New practices can form and hire staff.	Foreclosed; new entrants cannot attract labor due to UHG’s reimbursement dominance.

Defining the “Nurse Labor Market”

The investigation has placed specific emphasis on the home health and hospice sectors, where labor is the primary cost driver. The DOJ’s challenge to the Amedisys acquisition identified “local nurse labor markets” as the relevant antitrust market. The government presented evidence that in hundreds of counties, the combination of UnitedHealth (via LHC Group) and Amedisys would control a supermajority of nursing jobs. This concentration allows the merged entity to unilaterally depress wages or worsen shift conditions without fear of losing staff to competitors, a classic Section 7 violation.

This focus aligns with the Federal Trade Commission’s (FTC) 2024 ban on non-competes (though legally contested), signaling a unified federal stance that labor mobility is a serious component of market health. By applying this lens to UHG, the DOJ is testing the legal theory that “harm to competition” includes the suppression of workers’ earnings and freedom, not just the prices paid by their patients.

Divestiture Economics: Modeling the Financial Shock of an Optum Spin-Off

The financial architecture of UnitedHealth Group (UHG) relies on a massive, internal capital loop that the Department of Justice’s 2025 antitrust inquiry threatens to sever. While public discourse focuses on patient care and monopoly power, the core economic risk of a forced Optum spin-off lies in the “eliminations” column of UHG’s balance sheet. As of year-end 2025, this figure, representing revenue Optum generates solely from its parent company, UnitedHealthcare, swelled to nearly $168 billion. A regulatory order to separate these entities would not split a conglomerate; it would instantly convert $168 billion of guaranteed, captive revenue into at-risk, market-competitive income, fundamentally altering the valuation models of both entities.

The $168 Billion Internal Subsidy

The “flywheel” effect touted by UHG executives is statistically visible in the inter-segment eliminations reported in SEC filings. These funds represent premiums collected by UnitedHealthcare (the insurance arm) that are paid to Optum (the services arm) for pharmacy benefits, care delivery, and data analytics. In a consolidated model, this transfer is direct and margin-accretive. In a divestiture scenario, it becomes a transactional friction point.

Data from 2024 and 2025 highlights the escalating dependency between the two divisions:

Table 1: UnitedHealth Group Inter-Segment Revenue Eliminations (2024, 2025)

Fiscal Year	UnitedHealthcare Revenue	Optum Revenue	Gross Combined Revenue	Inter-Segment Eliminations	Eliminations as % of Optum Revenue
2024	$298. 2 Billion	$253. 0 Billion	$551. 2 Billion	$150. 9 Billion	59. 6%
2025	$344. 9 Billion	$270. 6 Billion	$615. 5 Billion	$167. 9 Billion	62. 0%

The data reveals that by 2025, nearly 62% of Optum’s top-line revenue was derived from its corporate sibling. A spin-off would expose this revenue to market forces. Independent insurers like Cigna or Aetna, who currently hesitate to use Optum due to its affiliation with a rival payer, might theoretically become customers. yet, the immediate shock would be the loss of “preferred status.” UnitedHealthcare would be legally obligated to seek the lowest-cost provider for services, chance forcing a standalone Optum to compress its margins to compete for the very contract it previously owned by default.

Margin Decompression and Operational Dis-Synergies

The profitability of a standalone Optum is currently overstated by the absence of customer acquisition costs (CAC) for its largest client. In 2025, Optum reported operating earnings of $9. 5 billion, a figure depressed by cyberattack remediation structurally supported by the zero-CAC volume from UnitedHealthcare. Analysts estimate that an independent Optum would require a 15% to 20% increase in Selling, General, and Administrative (SG&A) expenses to build a sales force capable of retaining the UnitedHealthcare contract and diversifying its client base.

Conversely, UnitedHealthcare’s margins would face immediate pressure. The “double marginalization” benefit, where UHG captures profit at both the insurance and provider levels, would. In 2025, UnitedHealthcare’s operating margin dipped to 2. 7% due to Medicare funding cuts. Without the ability to recapture medical spend through Optum’s profits, the insurance arm’s standalone valuation would likely realign with lower-margin pure-play insurers, shedding the “technology premium” currently in UHG’s stock price.

“The market cap of UnitedHealth Group is not the sum of its parts; it is the product of its integration. Removing the ability to shift regulated insurance dollars into unregulated service profits destroys the valuation multiplier.” , Sector Analyst Note, February 2026

The Amedisys Precedent: A Microcosm of Divestiture Costs

The economic friction of unwinding these assets was previewed in the December 2025 settlement regarding the Amedisys acquisition. To satisfy antitrust concerns, UHG agreed to divest 164 home health and hospice locations, representing approximately $528 million in annual revenue. While this figure is a fraction of the total enterprise, the transaction costs and operational disruptions were significant.

The Amedisys divestiture forced UHG to sell assets to competitors like The Pennant Group and BrightSpring Health Services. This transfer of assets created immediate competitors in markets where UHG previously held dominance. Scaling this logic to a full Optum spin-off suggests a chaotic transition period where hundreds of billions in assets, clinics, data centers, and pharmacy distribution hubs, must be re-valued and chance sold to private equity or rival health systems, triggering massive tax liabilities and operational disarray.

Valuation Arbitrage: The Sum-of-the-Parts Trap

Financial theorists frequently for a “sum-of-the-parts” valuation, suggesting that Optum, as a high-growth technology and services company, should trade at a higher earnings multiple (20x, 25x) than the consolidated entity. yet, this model assumes that Optum’s earnings quality would remain unchanged post-split. The 2025 market reaction to DOJ probes indicates investors are skeptical of this theory.

When news of the expanded DOJ investigation broke in early 2025, UHG stock suffered its worst single-day decline in a decade, wiping out over $35 billion in market capitalization. This volatility reflects the market’s understanding that the “Optum premium” is inextricably linked to the “UnitedHealthcare volume.” A split does not unlock value; it exposes the subsidy. If Optum were to trade as a standalone entity, its valuation would be heavily discounted until it could prove it can maintain 6% operating margins without the guaranteed $168 billion feed from its former parent.

Market Capitalization Sensitivity

The 2025 financial performance show the fragility of this integrated model. even with a 12% revenue growth to $447. 6 billion, UHG’s net earnings fell to $12. 1 billion. The compression of margins in both segments, Optum’s dropping to 3. 5% and UnitedHealthcare’s to 2. 7%, demonstrates that even with vertical integration, the company is facing headwinds. A divestiture would remove the primary lever UHG uses to manage these headwinds: the ability to shift costs and profits between regulated and unregulated pockets. Without this lever, the combined market capitalization of two independent companies could be 15% to 20% lower than the current consolidated value, representing a destruction of shareholder wealth exceeding $80 billion.

The following section profiles the presiding judicial authority in the 2025 UnitedHealth Group antitrust proceedings.

Judicial Assignment Profile: Analyzing Past Antitrust Rulings of the Presiding Court

The judicial oversight of the Department of Justice’s 2025 antitrust actions against UnitedHealth Group (UHG), specifically the challenge to the Amedisys acquisition, falls under the jurisdiction of the United States District Court for the District of Maryland. The presiding authority for the consent decree and divestiture order is Senior U. S. District Judge James K. Bredar. Appointed to the bench by President Barack Obama in 2010 and serving as Chief Judge from 2017 to 2024, Judge Bredar has established a reputation for rigorous management of complex structural reform cases, most notably through his decade-long supervision of the Baltimore Police Department (BPD) consent decree.

The Presiding Judge: James K. Bredar

Judge Bredar’s assignment to United States v. UnitedHealth Group Inc. and Amedisys Inc. (Case No. 1: 24-cv-03267-JKB) places the enforcement of the December 2025 divestiture order in the hands of a jurist experienced in long-term institutional monitoring rather than purely theoretical antitrust jurisprudence. Unlike judges who favor laissez-faire market interpretations, Bredar’s track record indicates a preference for active judicial supervision of settlement terms to ensure compliance.

His transition to senior status in April 2024 did not diminish his caseload regarding high- corporate and institutional oversight. Legal analysts note that his background as a former Federal Public Defender and his handling of the BPD civil rights consent decree suggest a skepticism toward institutional obfuscation, a trait relevant to the DOJ’s allegations of UHG’s “informational asymmetries” and evasion of regulatory caps.

Relevant Case History and Judicial Philosophy

While Judge Bredar’s docket has not been dominated by monopolization trials, his rulings in complex corporate litigation and ERISA class actions reveal a consistent method to corporate accountability and structural remedies.

Case / Litigation	Year	Relevance to UnitedHealth Group Antitrust Probe
United States v. UnitedHealth Group & Amedisys	2025	Entered Final Judgment requiring the divestiture of 164 clinics; appointed William Berlin as compliance monitor to oversee asset separation and prevent re-acquisition of market power.
Reed v. MedStar Health	2024	Approved an $11. 8 million settlement in an ERISA class action alleging mismanagement of retirement plans. Demonstrates willingness to penalize large healthcare entities for fiduciary failures.
Baltimore Police Dept. Consent Decree	2017, Present	Oversees one of the nation’s most detailed institutional reform decrees. His insistence on compliance and independent monitoring parallels the DOJ’s demand for a monitor in the UHG-Amedisys settlement.
T. Rowe Price 401(k) Litigation	2022	Approved a $7 million settlement regarding self-dealing allegations. The case established his intolerance for conflicts of interest within vertically integrated financial structures.

Oversight of the Amedisys Consent Decree

In the December 10, 2025, Final Judgment, Judge Bredar did not rubber-stamp the DOJ’s proposed settlement. The court’s order included specific provisions for a court-appointed monitor, William Berlin, to scrutinize UHG’s compliance. This mirrors Bredar’s method in the BPD consent decree, where he frequently utilized independent monitoring teams to bypass bureaucratic resistance and secure verified data.

The selection of the District of Maryland as the venue is also strategic. The court’s proximity to federal regulators in D. C., combined with its history of handling sensitive government litigation (including cases involving Booz Allen Hamilton and other federal contractors), provides a stable environment for the DOJ’s “fan-out” investigation. Judge Bredar’s specific mandate requires UHG to maintain the viability of the divested assets, preventing the “scuttling” tactics frequently used by monopolists to weaken spun-off competitors. His order explicitly retains jurisdiction to enforce these terms, signaling that the court remain an active participant in UHG’s operational restructuring throughout 2026.

“The Court retains jurisdiction to enable any party to this Final Judgment to apply to this Court at any time for further orders and directions as may be necessary or appropriate to carry out or construe this Final Judgment, to modify any of its provisions, to enforce compliance, and to punish violations of its provisions.”
, Excerpt from the Final Judgment, United States v. UnitedHealth Group Inc., Dec 10, 2025.

for Future Monopolization Charges

Should the DOJ’s broader 2025 investigation into UHG’s vertical integration (covering Optum and UnitedHealthcare) escalate to a new monopolization complaint, the District of Maryland remains a likely venue. Judge Bredar’s familiarity with UHG’s corporate structure through the Amedisys proceedings establishes a judicial baseline. His demonstrated intolerance for “performative compliance”, where institutions tick boxes without changing underlying behavior, poses a significant risk to UHG’s defense strategy, which relies heavily on technical separation of its business units while maintaining unified control.

The ‘Patients Over Profits’ Act: Legislative Threats to the Vertical Model

The “Nuclear Option”: Legislative Escalation in 2025

On September 17, 2025, the legislative regarding healthcare consolidation shifted from regulatory oversight to existential threat with the introduction of the Patients Over Profits Act. Sponsored by Senators Jeff Merkley (D-OR) and Elizabeth Warren (D-MA), along with Representatives Val Hoyle (D-OR) and Pat Ryan (D-NY), the bill represents the federal legislative attempt to explicitly the “payvider” model that defines UnitedHealth Group (UHG). Unlike previous antitrust measures that focused on merger review or transparency, this legislation the structural core of vertical integration: the simultaneous ownership of health insurance plans and clinical care delivery systems.

The Act was drafted largely in response to the aggressive expansion of Optum, UHG’s health services arm, which by late 2025 controlled approximately 10% of the active United States physician workforce. Legislators the collapse of patient access at the Oregon Medical Group, acquired by Optum in 2020, as a primary case study. Following the acquisition, the practice reportedly saw a mass exodus of physicians and the subsequent dismissal of thousands of patients, a pattern lawmakers argued was emblematic of corporate prioritization of risk-adjustment profits over care continuity.

Core Provisions: The Two-Year Divestiture Mandate

The central method of the Patients Over Profits Act is a prohibition on “common ownership” of health insurers and Medicare Part B or Part C providers. If enacted, the legislation would trigger a mandatory divestiture period, forcing entities like UnitedHealth Group to spin off their provider networks within two years. This provision directly attacks the financial feedback loop identified by DOJ investigators, wherein UHG allegedly steers premiums from its regulated insurance entity (UnitedHealthcare) to its unregulated provider arm (Optum) to evade Medical Loss Ratio (MLR) caps.

The bill’s scope extends beyond simple ownership bans. It precludes the Department of Health and Human Services (HHS) from contracting with any Medicare Advantage Organization (MAO) that retains ownership of clinical practices. For UHG, which derives over $140 billion annually from government-sponsored health programs, this clause renders non-compliance an operational impossibility.

Table: Key Provisions of the Patients Over Profits Act (S. 2025-POP)

Section	Provision Detail	Operational Impact on UHG
Prohibition on Vertical Ownership	Bans insurance companies from owning, operating, or managing Medicare Part B (outpatient) or Part C (Medicare Advantage) providers.	Would require the full divestiture of Optum Care’s 90, 000+ physician network.
Divestiture Timeline	Mandates a strict 24-month window for non-compliant entities to sell off provider assets to independent third parties.	Forces a “fire sale” of assets, preventing gradual offloading or internal restructuring.
Contractual Bar	Prohibits HHS from signing Medicare Advantage contracts with insurers who violate the ownership ban.	Threatens UHG’s primary revenue stream (Medicare Advantage), creating an immediate solvency risk.
Enforcement Authority	the FTC, DOJ, and State Attorneys General to bring civil actions and claw back profits derived from prohibited structures.	Opens UHG to simultaneous litigation from federal regulators and 50 state jurisdictions.

The “Pincer Movement”: Legislation Meets Litigation

While the Patients Over Profits Act faces a steep climb in a divided Congress, its introduction serves a strategic function in the broader antitrust offensive. Legal analysts describe the bill as the legislative arm of a “pincer movement,” operating in tandem with the Department of Justice’s ongoing monopolization probe. The DOJ’s investigation focuses on current violations of the Sherman Act, while the legislative push signals to the judiciary and the market that the future political consensus is moving toward structural separation.

This dual pressure has already impacted market sentiment. Following the bill’s introduction and the subsequent Senate Judiciary Committee hearings in late 2025, UHG’s stock volatility increased, reflecting investor anxiety that the vertical integration premium, once considered a moat, had become a liability. The bill also emboldened state-level regulators. In Massachusetts and Oregon, state legislatures introduced “mini-POP” bills in early 2026, aiming to restrict insurer ownership of physician practices within their specific jurisdictions, bypassing federal gridlock.

Industry Defense and the “Value-Based” Counter-Narrative

UnitedHealth Group has mounted a vigorous defense against the legislation, deploying a lobbying campaign centered on the efficiency of “value-based care.” In testimony before the Senate Finance Committee in October 2025, UHG executives argued that vertical integration is necessary to coordinate care, reduce hospital admissions, and lower in total health spending. They contended that forced divestiture would fragment the healthcare system, returning the market to a “fee-for-service” model that incentivizes volume over quality.

yet, the credibility of this defense has been eroded by the concurrent release of the Senate Judiciary Committee’s report on “coding intensity.” The report revealed that UHG’s vertical model was primarily used to maximize risk-adjustment payments rather than improve clinical outcomes. By linking the legislative text to these investigative findings, sponsors of the Patients Over Profits Act have framed the bill not just as antitrust enforcement, as a necessary measure to protect the Medicare Trust Fund from widespread looting.

“Your doctor’s office should be in the business of making sure you get the best possible care, not functioning as a profit center for billionaire health care corporations. The Patients Over Profits Act reins in these out-of-control consolidations, which are great for corporate greed and a bad deal for patients.”
, Senator Jeff Merkley (D-OR), Press Release, September 17, 2025.

The following is an investigative report section on the 2026 Litigation Timeline for the DOJ’s antitrust investigation into UnitedHealth Group.

Section 24: 2026 Litigation Timeline: Discovery Deadlines and Federal Trial Projections

As of February 25, 2026, the legal surrounding UnitedHealth Group (UHG) has bifurcated into two distinct tracks: the concluded consent decree regarding the Amedisys acquisition and the accelerating pre-trial phase of the Department of Justice’s (DOJ) broader monopolization inquiry. While the December 10, 2025, Final Judgment in United States v. UnitedHealth Group Inc. resolved the immediate merger challenge, the Antitrust Division’s structural investigation into Optum’s vertical integration has entered a serious procedural window. Federal prosecutors are coordinating discovery schedules with state attorneys general, setting the stage for what legal analysts project be the largest healthcare antitrust litigation in U. S. history.

The Monopolization Probe: Anticipated Filing and Pre-Trial Schedule

Following the “unusually quiet” period noted by industry observers in late 2025, the DOJ is expected to file a detailed monopolization complaint under Section 2 of the Sherman Act by Q2 2026. This anticipated filing the “flywheel” effect between UnitedHealthcare’s insurance arm and Optum’s care delivery network. Based on standard federal antitrust dockets and the of the investigation, the projected litigation timeline extends into late 2029.

Projected Federal Litigation Timeline: United States v. UnitedHealth Group (Monopolization Track)

Phase	Projected Window	Key Milestones & Deadlines
Complaint Filing	Q2 2026 (April, June)	DOJ and coalition of State AGs file complaint in D. D. C. or D. Minn.; UHG files Motion to Dismiss (MTD) within 60 days.
Initial Discovery	Q3 2026 , Q4 2027	Production of internal emails, “nH Predict” algorithm source code, and reimbursement rate tables.
Fact Witness Depositions	Q1 2027 , Q3 2027	Depositions of UHG executives, independent physician groups, and rival payers.
Expert Discovery	Q4 2027 , Q1 2028	Economic analysis of vertical foreclosure; submission of expert reports on market definition and consumer harm.
Summary Judgment	Q2 2028	Both parties file dispositive motions; court rules on admissibility of expert testimony (Daubert motions).
Federal Trial	Q1 2029	Bench trial commences; expected duration 12, 16 weeks.

Active Discovery: The Unsealed “Whistleblower” Docket

While the monopolization case looms, UHG is already navigating active discovery deadlines in the qui tam (whistleblower) litigation unsealed in September 2025. This parallel civil fraud track, which overlaps with the DOJ’s criminal probe into Medicare Advantage billing, has generated immediate production obligations. The U. S. District Court has set strict deadlines for the production of risk-adjustment data, a dataset that is also central to the antitrust theory of “upcoding” as a method to subsidize vertical acquisitions.

Judicial Order Excerpt (Civil Docket No. 25-cv-0912):
“Defendant shall produce all internal communications regarding the ‘Projected Risk Score’ metrics used by Optum Home & Community for the period of January 1, 2020, through December 31, 2025. Production must be completed by March 15, 2026. Failure to comply result in evidentiary sanctions.”

This discovery order forces UHG to hand over sensitive data regarding its “Chart Review” programs just as the antitrust division finalizes its monopolization complaint. The convergence of these timelines creates a tactical disadvantage for UHG defense counsel, who must defend the integrity of their billing algorithms in one court while simultaneously arguing those same algorithms do not constitute an exclusionary barrier to entry in another.

The Criminal Probe: Grand Jury Proceedings

The criminal investigation into UHG’s Medicare billing practices, confirmed by the company in mid-2025, operates on a separate, secretive timeline. As of February 2026, the grand jury empanelled in the Eastern District of New York continues to hear testimony. Unlike civil litigation, this track has no public docket, its existence influences the civil discovery strategy. UHG executives deposed in the civil antitrust case may invoke Fifth Amendment rights to avoid self-incrimination regarding the billing fraud allegations, a move that could lead to adverse inferences in the civil trial.

Post-Judgment Compliance: The Amedisys Monitor

The December 10, 2025, Final Judgment regarding the Amedisys acquisition imposed a ten-year compliance period. A court-appointed monitor is currently auditing the divestiture of 164 locations to Pennant Group and BrightSpring Health Services. The compliance report is due to the DOJ on June 10, 2026. Any violation of the “firewall” provisions, designed to prevent UHG from accessing sensitive data of the divested assets, could trigger immediate contempt proceedings and provide fresh evidence of anticompetitive intent for the broader monopolization case.

Strategic for 2026

The year 2026 represents a transition from investigation to active litigation. The “quiet period” of late 2025 was not a cessation of activity a preparatory phase for the DOJ’s litigation team. With the Amedisys divestiture secured, regulators have cleared the deck to focus entirely on the structural breakup of the UnitedHealth-Optum nexus. The discovery deadlines set for March and April 2026 in the whistleblower case likely yield the public tranches of evidence regarding the company’s internal valuation of its vertical integration strategy, data that form the evidentiary backbone of the government’s case for the remainder of the decade.